var title_f11_51_12080="Intrauterine adhesion hysterosc";
var content_f11_51_12080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopic image of adhesive band bridging from anterior to posterior uterine wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marcelle Cedars, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12080=[""].join("\n");
var outline_f11_51_12080=null;
var title_f11_51_12081="Patient information: Autoimmune hemolytic anemia (The Basics)";
var content_f11_51_12081=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Autoimmune hemolytic anemia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/autoimmune-hemolytic-anemia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H12629217\">",
"      <span class=\"h1\">",
"       What is autoimmune hemolytic anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Autoimmune hemolytic anemia is a rare type of anemia. Anemia is a condition that happens when a person has too few red blood cells. Red blood cells are the cells in your blood that carry oxygen. If you have too few red blood cells, your body does not get all the oxygen it needs.",
"     </p>",
"     <p>",
"      Autoimmune hemolytic anemia happens due to problems with the body&rsquo;s infection-fighting system, called the &ldquo;immune system.&rdquo; Normally, the immune system kills germs and other bad cells that could turn into cancer. If something goes wrong and the immune system starts to attack healthy cells, it is called an &ldquo;autoimmune response.&rdquo; If your immune system attacks and destroys your red blood cells, you get autoimmune hemolytic anemia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12629232\">",
"      <span class=\"h1\">",
"       What causes autoimmune hemolytic anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors don&rsquo;t know what causes the condition in about half of the people who get it. In rare cases, certain medicines used to treat infections and pain cause autoimmune hemolytic anemia. Other possible causes include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Infections such as pneumonia and mononucleosis (also called &ldquo;mono&rdquo;).",
"       </li>",
"       <li>",
"        Certain types of cancer, including &ldquo;leukemia&rdquo; (cancers of the blood) and &ldquo;lymphoma.&rdquo; Lymphomas are cancers that affect organs in the body that make and store infection-fighting cells.",
"       </li>",
"       <li>",
"        Autoimmune diseases such as lupus - In people with lupus, the immune system attacks cells and organs all over the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      But most people with these diseases do NOT get autoimmune hemolytic anemia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12629249\">",
"      <span class=\"h1\">",
"       What are the symptoms of autoimmune hemolytic anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A pale color in the tissue that lines the inside of the eyelid &ndash; You can see this tissue (called &ldquo;conjunctivae&rdquo;) by gently pulling down your lower eyelid. The tissue will appear pale instead of its normal, pinkish-red color.",
"       </li>",
"       <li>",
"        Dark yellow urine",
"       </li>",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        A fast heartbeat",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Headache and muscle pains",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have light-colored skin, your skin may become pale or yellow.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12629264\">",
"      <span class=\"h1\">",
"       Is there a test for autoimmune hemolytic anemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors use many different blood tests to check for autoimmune hemolytic anemia. The most important one is called the &ldquo;Coombs test.&rdquo; This test checks for signs of an immune attack on your red blood cells.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H12629279\">",
"      <span class=\"h1\">",
"       How is autoimmune hemolytic anemia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines that make your body&rsquo;s immune system less active, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"         prednisone",
"        </a>",
"        .",
"       </li>",
"       <li>",
"        Surgery to remove an organ called the spleen (called a &ldquo;splenectomy&rdquo;)",
"       </li>",
"      </ul>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/51/12081?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83062 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12081=[""].join("\n");
var outline_f11_51_12081=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12629217\">",
"      What is autoimmune hemolytic anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12629232\">",
"      What causes autoimmune hemolytic anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12629249\">",
"      What are the symptoms of autoimmune hemolytic anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12629264\">",
"      Is there a test for autoimmune hemolytic anemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12629279\">",
"      How is autoimmune hemolytic anemia treated?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_51_12082="Bronch atresia bronchogram";
var content_f11_51_12082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchial atresia in infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A Bronchogram performed with oily Dionosil shows an absent superior division of the left upper lobe bronchus, with the lingular and left lower lobe bronchi displaced caudad.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12082=[""].join("\n");
var outline_f11_51_12082=null;
var title_f11_51_12083="Prurigo nodularis 2";
var content_f11_51_12083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prurigo nodularis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple nodules, some of which excoriated, on the lower limb of a patient with nodular prurigo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12083=[""].join("\n");
var outline_f11_51_12083=null;
var title_f11_51_12084="Amcinonide: Drug information";
var content_f11_51_12084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amcinonide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/54/39779?source=see_link\">",
"    see \"Amcinonide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amcort&reg;;",
"     </li>",
"     <li>",
"      Cyclocort&reg;;",
"     </li>",
"     <li>",
"      ratio-Amcinonide;",
"     </li>",
"     <li>",
"      Taro-Amcinonide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Steroid-responsive dermatoses: Topical: Apply in a thin film 2-3 times/day. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.1% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 0.1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 0.1% (30 g [DSC], 60 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (high potency corticosteroid)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F132815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, hypopigmentation, allergic dermatitis, maceration of the skin, miliaria, skin atrophy, striae, telangiectasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cushing's syndrome, growth retardation (long-term use), HPA axis suppression, hyperglycemia; these reactions occur more frequently with occlusive dressings",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, dryness, folliculitis, hypertrichosis, itching, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Secondary infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F132794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amcinonide or any component of the formulation; use on the face, groin, or axilla",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F132780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infected/weeping lesions: Occlusive dressings should not be used in presence of infection or weeping lesions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F132786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13332958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animals administered potent topical corticosteroids. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13332960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13332959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if topical application will result in detectable quantities in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F132795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Amcinonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (30 g): $38.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lotion",
"     </b>",
"     (Amcinonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (60 mL): $325.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Amcinonide External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (60 g): $388.80",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F132796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amciderm (DE, TH);",
"     </li>",
"     <li>",
"      Amcinil (IT);",
"     </li>",
"     <li>",
"      Amicla (BE, LU, NL);",
"     </li>",
"     <li>",
"      Penticort (FR, IT);",
"     </li>",
"     <li>",
"      Visderm (AR, JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F132779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates the synthesis of enzymes needed to decrease inflammation, suppress mitotic activity, and cause vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F132793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Adequate through intact skin; increases with skin inflammation or occlusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?11/51/12084/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8513 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12084=[""].join("\n");
var outline_f11_51_12084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132802\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132817\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132803\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132804\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132789\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132776\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132790\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132815\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132794\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132780\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298730\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132785\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132786\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13332958\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13332960\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13332959\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132795\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132796\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132779\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132793\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8513\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8513|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/54/39779?source=related_link\">",
"      Amcinonide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_51_12085="Left bundle branch block 1";
var content_f11_51_12085=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Complete left bundle branch block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 139px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Delayed and abnormal activation of the left ventricular myocardium, and a diffuse slowing of conduction throughout the left ventricle leads to the following changes on the ECG: there is a tall monophasic and broadened R wave in leads I, aVL, and V6 instead of a septal Q wave; there is a QS complex which is abnormal and widened in V1 instead of a small initial R wave due to septal activation; the QRS interval is prolonged &gt;0.12 seconds; myocardial repolarization changes including T wave inversion and ST segment depression are evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12085=[""].join("\n");
var outline_f11_51_12085=null;
var title_f11_51_12086="Biopsy specimen histo";
var content_f11_51_12086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Biopsy specimen from a facial lesion (gomori methenamine silver stain; original magnification, x600)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lesho, E, Gunning, S, Wortmann, G. An AIDs patient with fever and rash. Clin Infect Dis 2005; 41:75. Copyright &copy;2005 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12086=[""].join("\n");
var outline_f11_51_12086=null;
var title_f11_51_12087="Fetal thrombotic vasculopathy";
var content_f11_51_12087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59894&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal thrombotic vasculopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large portion of the villous tree (&gt;15 villi/slide) shows loss of fetal vessels and hyaline fibrosis secondary to upstream vascular occlusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Raymond W. Redline, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12087=[""].join("\n");
var outline_f11_51_12087=null;
var title_f11_51_12088="Thin basement membrane nephropathy (benign familial hematuria)";
var content_f11_51_12088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thin basement membrane nephropathy (benign familial hematuria)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/51/12088/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/51/12088/contributors\">",
"     Clifford E Kashtan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/51/12088/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/51/12088/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/51/12088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/51/12088/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/51/12088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thin basement membrane nephropathy (TBMN, also called thin basement membrane disease and benign familial hematuria) is a relatively common disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/1\">",
"     1",
"    </a>",
"    ]. The only finding on renal biopsy is diffuse thinning of the glomerular basement membranes requiring electron microscopy for the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This disorder is often familial, with a family history of hematuria being noted in 30 to 50 percent of cases. TBMN seems to account for most cases of what has been called benign familial hematuria. Several mutations of the type IV collagen genes COL4A3 and COL4A4 have been identified in patients with thin basement membrane nephropathy, but such mutations are not present in all families [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thin basement membrane nephropathy will be discussed in this topic review. Alport syndrome is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies on kidneys used for renal transplantation suggest that the frequency of thin basement membranes in the general population may be as high as 5 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, thin basement membrane disease is clinically diagnosed is less than 1 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It had been suspected that the genetic defect in thin basement membrane nephropathy would be similar to that in hereditary nephritis (Alport syndrome), since patients with the latter group of disorders also have thin basement membranes early in the course of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/9\">",
"     9",
"    </a>",
"    ]. This hypothesis has been confirmed in families in which thin basement membrane nephropathy was due to heterozygous defects in COL4A3 or COL4A4, the genes that encode for the alpha-3 and alpha-4 chains of type IV collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/8,10-15\">",
"     8,10-15",
"    </a>",
"    ]. The entire group of disorders encompassing TBMN and Alport syndrome has been called the Type IV Collagen Nephropathies.",
"   </p>",
"   <p>",
"    Patients with TBMN can be considered \"carriers\" of autosomal recessive Alport syndrome, since mutations in both alleles of COL4A3 or COL4A4 cause autosomal recessive Alport syndrome (ARAS) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/16\">",
"     16",
"    </a>",
"    ]. Mutations in both alleles can be the same (homozygous) or different (compound heterozygous). Approximately 40 to 50 percent of heterozygous carriers of a COL4A3 or COL4A4 mutation in Alport families exhibit microhematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although both alleles of COL4A3 or COL4A4 must be involved to produce autosomal recessive Alport syndrome (ARAS), thin basement membrane nephropathy is transmitted in a dominant fashion because the abnormal gene product produces a defect in collagen that is sufficiently severe to interfere with the normal architecture of glomerular basement membranes, resulting in hematuria. In most cases, however, the heterozygous defect does not provoke the secondary processes that result in the proteinuria, impaired glomerular filtration, and glomerulosclerosis observed in patients with Alport syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Linkage with the COL4A3 and COL4A4 genes has not been found in all families with thin basement membrane nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The underlying defect(s) in these other families are not known. Possibilities include de novo mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/23\">",
"     23",
"    </a>",
"    ], incomplete penetrance, or novel genetic loci.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TBMN is often familial, probably with autosomal dominant inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/2\">",
"     2",
"    </a>",
"    ]. A family history of hematuria is noted in 30 to 50 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Microscopic hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic manifestation of thin basement membrane nephropathy is persistent or intermittent asymptomatic microscopic hematuria incidentally discovered on routine urinalysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/1\">",
"     1",
"    </a>",
"    ]. It has been proposed that red cells enter Bowman's space in TBMN by moving through localized gaps in the glomerular capillary wall [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in other glomerular diseases, dysmorphic red cells and, in some patients, red blood cell casts can be seen on examination of the urine sediment in patients with TBMN [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/8,25\">",
"     8,25",
"    </a>",
"    ]. Episodes of macroscopic hematuria are uncommon, unlike those seen in IgA nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=see_link\">",
"     \"Clinical presentation and diagnosis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been proposed that the hematuria in thin basement membrane nephropathy represents an exaggeration of the normal process of naturally occurring spontaneous ruptures in the glomerular basement membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/26\">",
"     26",
"    </a>",
"    ]. These ruptures may also account for the small number of red cells excreted in normal urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Gross hematuria and flank pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with TBMN may have episodes of gross (macroscopic) hematuria. These episodes may be preceded by an upper respiratory tract infection, simulating poststreptococcal glomerulonephritis and IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14578038#H14578038\">",
"     \"Differential diagnosis and evaluation of glomerular disease\", section on 'Hematuria following upper respiratory infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gross hematuria in TBMN may be associated with flank (loin) pain, simulating the clinical picture of loin pain-hematuria syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/8,27,28\">",
"     8,27,28",
"    </a>",
"    ]. These episodes are often associated with hypercalciuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperuricosuria, which are risk factors for both stone formation and hematuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35881?source=see_link\">",
"     \"Loin pain-hematuria syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These relationships were illustrated in a study of 46 individuals with biopsy proven TBMN or first-degree relatives with persistent microscopic hematuria in which the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      18 (39 percent) had hypercalciuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperuricosuria, which are important risk factors for nephrolithiasis, and 25 percent of those with proven disease had a history of previous nephrolithiasis. These values were much higher than in patients with IgA nephropathy or normal controls (eg, 3 percent of IgA nephropathy patients had a history of nephrolithiasis).",
"     </li>",
"     <li>",
"      The TBMN patients and microhematuric first-degree relatives with hypercalciuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hyperuricosuria had, when compared to those with normal calcium and uric acid excretion, significantly higher rates of episodes of gross hematuria (44 versus 7 percent) and episodes of loin pain (27 versus 3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, renal tubular injury and obstruction may be promoted by the simultaneous presence of red cells and microcrystals in the tubular lumen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case report described the development of acute renal failure and gross hematuria developing after overanticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (INR 3.6 versus prior values of 1.7 to 1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/29\">",
"     29",
"    </a>",
"    ]. Renal biopsy showed, in addition to thin basement membranes, distension of many renal tubules by intratubular red cells and tubular cell injury consistent with acute tubular necrosis. The patient required hemodialysis for six weeks, and the serum creatinine had returned to close to baseline levels (1.3 versus 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at baseline [115 versus 88",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    at six months.",
"   </p>",
"   <p>",
"    Acute renal failure associated with gross hematuria with similar pathologic findings and clinical course have been described in patients with IgA nephropathy independent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prognosis of IgA nephropathy\", section on 'Acute renal failure with gross hematuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Other renal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary protein excretion and blood pressure are typically normal in patients with TBMN. However, some patients have minimal to moderate proteinuria (usually less than 1.5",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    rarely in the nephrotic range)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/2-4,15,19,30-32\">",
"     2-4,15,19,30-32",
"    </a>",
"    ]. It is not known if such patients have unrecognized Alport syndrome, represent a more severe phenotype of TBMN, or have another gene polymorphism influencing their course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of thin basement membrane nephropathy (TBMN) is usually inferred from the benign presentation and course, the positive family history of hematuria, and the negative family history of renal failure. Renal biopsy is generally NOT performed in patients who present with isolated glomerular hematuria, no or minimal proteinuria, and normal renal function. The prognosis is excellent in such patients unless the clinical manifestations progress, as occurs in all males and some females with hereditary nephritis and many patients with IgA nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=see_link\">",
"     \"Treatment and prognosis of IgA nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Indications for renal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that renal biopsy generally be limited to patients with suspected TBMN who also have proteinuria (&gt;200 to 300",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    There are, however, some settings in which renal biopsy might be considered in patients with hematuria alone:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the patient being considered as a kidney donor?",
"     </li>",
"     <li>",
"      Is marriage to another individual with isolated hematuria being planned?",
"     </li>",
"     <li>",
"      Is there an issue concerning the purchase of life or disability insurance?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal biopsy reveals diffuse thinning of the glomerular basement membranes on electron microscopy (GBM width usually between 150 and 225 nM, versus 300 to 400 nM in normal subjects) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55486 \" href=\"UTD.htm?34/50/35624\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. TBMN requires electron microscopy for histologic diagnosis; it cannot be diagnosed by examination of the biopsy specimen by light microscopy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thin basement membrane nephropathy must be distinguished from the other common glomerular causes of isolated hematuria: IgA nephropathy and hereditary nephritis (Alport syndrome). TBMN and IgA nephropathy are the most common disorders underlying asymptomatic hematuria, together accounting for 50 percent or more of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The history and clinical presentation are often helpful in distinguishing between these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/2/17445?source=see_link\">",
"     \"Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with IgA nephropathy often have episodes of gross hematuria and a negative family history; the latter is unusual in thin basement membrane nephropathy as is gross hematuria in the absence of hypercalciuria or hyperuricosuria [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with Alport syndrome also may have gross hematuria and typically have a family history of renal failure, most frequently affecting males since most families have X-linked inheritance. The next section reviews this distinction in more detail.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Distinction from Alport syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of the similarities in early histologic changes and in pathogenesis, thin basement membrane nephropathy may be difficult to distinguish from hereditary nephritis in some cases. The following clinical and histologic parameters usually permit the correct diagnosis to be made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening first-degree relatives for hematuria often suggests the diagnosis of thin basement membrane nephropathy. In view of its autosomal dominant inheritance, roughly 50 percent of first-degree relatives should have hematuria [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/7,25\">",
"       7,25",
"      </a>",
"      ]. Furthermore, father-to-son transmission may be present, a finding that is not seen in X-linked hereditary nephritis.",
"     </li>",
"     <li>",
"      Patients with thin basement membrane nephropathy do not have hearing loss, ocular abnormalities, or a prominent family history of renal failure [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/35\">",
"       35",
"      </a>",
"      ]. With X-linked Alport syndrome, hearing loss is often observed in childhood, but ocular abnormalities may not be evident until the third decade of life [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some evidence suggests that skin biopsy may be a direct way to distinguish between these disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/36\">",
"       36",
"      </a>",
"      ]. Incubation of the biopsy specimen with a monoclonal antibody directed against the alpha-5 chain of type IV collagen (which is the site of the primary abnormality in hereditary nephritis) shows no staining along the epidermal basement membrane in most males with X-linked Alport syndrome, discontinuous staining in females with X-linked disease, and normal staining in thin basement membrane nephropathy. Since some patients with X-linked Alport syndrome and all patients with autosomal recessive Alport syndrome have normal epidermal basement membrane staining for the alpha-5(IV) chain, this test can confirm a suspected diagnosis of Alport syndrome, but cannot by itself exclude the diagnosis.",
"     </li>",
"     <li>",
"      Although renal biopsy may reveal thin basement membranes as the only abnormality in early hereditary nephritis [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/9\">",
"       9",
"      </a>",
"      ], incubation of kidney tissue with antibodies against the alpha-3, -4 and &ndash;5 chains of type IV collagen usually reveals absence of staining in hereditary nephritis and always shows the presence of staining in thin basement membrane nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/8,35\">",
"       8,35",
"      </a>",
"      ]. However, the ability to reasonably exclude Alport syndrome based upon staining patterns varies based upon age and gender. It is difficult to entirely exclude autosomal recessive Alport syndrome (ARAS) or X-linked Alport syndrome (XLAS) in the child with hematuria, thin basement membranes, and normal immunostaining for type IV collagen. Molecular testing for COL4A3, COL4A4, and COL4A5 mutations may help, although only COL4A5 analysis is currently commercially available in the United States. In addition, failure to find a mutation does not entirely exclude Alport syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, ARAS is unlikely (but possible) in an adult patient with hematuria and thin basement membranes. XLAS is also very unlikely in an adult male with isolated hematuria and thin basement membranes. However, in an adult female with isolated hematuria and thin basement membranes, normal immunostaining for type IV collagen cannot entirely exclude XLAS.",
"   </p>",
"   <p>",
"    Immunostaining may not be necessary in all patients with suspected thin basement membrane nephropathy. Such staining is not required, for example, in the patient with isolated hematuria and thin glomerular basement membrane who has a positive family history of hematuria but a negative history for renal failure. By comparison, immunostaining should be considered in sporadic cases (ie, patients who have no relatives with hematuria), in patients with thin glomerular basement membrane and a family history of kidney failure, and in patients with thin glomerular basement membrane and elevated urine protein levels. In patients with suspected thin basement membrane nephropathy, the normal expression of type IV collagen alpha chains in the glomerular basement membrane provides supportive evidence but cannot entirely exclude Alport syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis is excellent in most patients with true thin basement membrane nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/2,3,37\">",
"     2,3,37",
"    </a>",
"    ]. However, slowly progressive renal insufficiency can occur and is often manifested on renal biopsy by focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/2,3,7\">",
"     2,3,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been unclear whether thin basement membrane nephropathy was responsible for the progressive glomerular injury or was an incidental finding in patients with underlying focal segmental glomerulosclerosis (FSGS). In one study, for example, the incidence of thin basement membrane nephropathy in all patients with biopsy proven FSGS was 5 percent, similar to that in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, some patients with thin basement membranes and progressive renal dysfunction actually have Alport syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some data suggest that FSGS and slowly progressive renal insufficiency may be more common than previously suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 19 normotensive and nonazotemic patients with biopsy-proven thin basement membrane nephropathy (in whom clinical and histologic criteria tended to exclude hereditary nephritis) reported an increased incidence of focal global sclerosis on renal biopsy compared to matched controls with IgA nephropathy (13.5 versus 5.1 percent of glomeruli) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/35\">",
"       35",
"      </a>",
"      ]. In addition, family history revealed that 6 of 89 first-degree relatives (all of whom were elderly) had renal failure compared to 1 of 129 with IgA nephropathy. At the end of 12-year follow-up, three of seven subjects over age 50 had a modest decline in glomerular filtration rate (64 to 79",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"     </li>",
"     <li>",
"      In a prospective regional study in the Netherlands, 71 of 92 patients (77 percent) with biopsy-proven thin basement membrane nephropathy had hematuria without proteinuria [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/33\">",
"       33",
"      </a>",
"      ]. However, 16 had proteinuria of at least 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      (17 percent), while 5 had the nephrotic syndrome (5 percent). Eleven with significant proteinuria also had focal segmental glomerulosclerosis on renal biopsy, with the tip lesion being associated with the nephrotic syndrome in some patients.",
"     </li>",
"     <li>",
"      A study of 116 patients from 13 Greek-Cypriot families identified 20 with biopsy-proven FSGS and thin basement membrane nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/39\">",
"       39",
"      </a>",
"      ]. The 20 patients had chronic renal failure of varying severity, with some developing end-stage renal disease. However, renal dysfunction was not confined to those with FSGS; 11 additional patients with a specific mutation in the COL4A3 or COL4A4 genes but without FSGS also developed chronic renal failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that either the presence of proteinuria or a positive family history of chronic renal failure may portend a less benign prognosis for individuals with thin basement membrane disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The great majority of people with isolated hematuria, thin basement membrane nephropathy, and negative family history for renal failure maintain normal renal function and normal urine protein excretion on follow-up. However, in my view, follow-up is essential in order to identify those individuals who, for whatever reason, exhibit a progressive disease course.",
"   </p>",
"   <p>",
"    The frequency of thin basement membranes in the general population means that it will often be found as an incidental finding in other renal diseases such as diabetic nephropathy, lupus nephritis, membranous glomerulopathy, minimal change disease, and IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/7\">",
"     7",
"    </a>",
"    ]. In diabetic nephropathy, for example, thin basement membrane nephropathy may be responsible for otherwise unexplained hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/41\">",
"     41",
"    </a>",
"    ]. It has been suggested that thin basement membrane nephropathy may occur with slightly increased frequency in patients with IgA nephropathy, particularly among those with a family history of IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/37\">",
"     37",
"    </a>",
"    ]. It is unclear if there is a true relation between these disorders or if thin membranes might increase the severity of concurrent IgA nephropathy.",
"   </p>",
"   <p>",
"    As noted above, occasional patients have recurrent episodes of gross hematuria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flank pain. The administration of an angiotensin converting enzyme inhibitor may be beneficial in this setting, perhaps by lowering the intraglomerular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, treating hypercalciuria or hyperuricosuria, if present, has reduced hematuria in other patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12088/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No prospective controlled studies have evaluated the efficacy of therapy in patients with thin basement membrane nephropathy. Based principally upon benefits observed in patients with proteinuria and other forms of chronic kidney disease, we suggest the administration of an angiotensin II enzyme inhibitor or angiotensin II receptor blocker in patients with thin basement membrane nephropathy who also have",
"    <strong>",
"     proteinuria above 1",
"     <span class=\"nowrap\">",
"      g/day",
"     </span>",
"    </strong>",
"    ,",
"    particularly if they also have an elevation in blood pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevation in serum creatinine or reduction in estimated glomerular filtration rate. Data are not available on the efficacy of such an approach in proteinuric thin basement membrane nephropathy but, when used, both the proteinuria and blood pressure goals should be the same as those in other forms of proteinuric chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=see_link\">",
"       \"Patient information: Glomerular disease overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thin basement membrane nephropathy (TBMN, also called benign familial hematuria) is common. Although thin basement membranes can be seen in 5 to 9 percent of biopsy specimens, it is clinically diagnosed in less than 1 percent of the population. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heterozygous defects in COL4A3 or COL4A4, the genes that encode for the alpha-3 and alpha-4 chains of type IV collagen, are responsible for this disorder in 40 to 50 percent of affected families. Patients with these heterozygous mutations can be considered \"carriers\" of autosomal recessive Alport syndrome, since mutations in both alleles of COL4A3 or COL4A4 cause autosomal recessive Alport syndrome (ARAS). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A family history of hematuria is noted in 30 to 50 percent of cases, most commonly with autosomal dominant inheritance. The characteristic manifestation of thin basement membrane nephropathy is persistent or intermittent asymptomatic glomerular hematuria. Most frequently, urinary protein excretion, blood pressure, and renal function are normal. Some patients have minimal to moderate proteinuria (usually less than 1.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      rarely in the nephrotic range)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension. The invariable finding on renal biopsy with TBMN is diffuse thinning of the glomerular basement membranes on electron microscopy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is usually inferred from the benign presentation and course, the positive family history of hematuria, and the negative family history of renal failure. Renal biopsy is generally NOT performed in patients who present with isolated glomerular hematuria, no or minimal proteinuria, and normal renal function. However, we recommend the performance of a renal biopsy among patients with suspected thin basement membrane nephropathy (eg, glomerular hematuria) PLUS proteinuria (defined as greater than 200",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      Thin basement membrane nephropathy must be distinguished from the other common glomerular causes of isolated hematuria: IgA nephropathy and Alport syndrome. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most patients, an excellent long-term prognosis is observed. However, slowly progressive renal insufficiency can occur and is often manifested on renal biopsy by focal segmental glomerulosclerosis. Follow-up is essential to identify those individuals who exhibit a progressive disease course. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with thin basement membrane nephropathy PLUS any degree of abnormal proteinuria (greater than 200",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      we suggest the administration of an angiotensin II enzyme inhibitor therapy or angiotensin II receptor blocker therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The goals of therapy are unclear. In adults, we suggest a minimum reduction in proteinuria of at least 60 percent from baseline values and a target blood pressure of less than",
"      <span class=\"nowrap\">",
"       130/80",
"      </span>",
"      mmHg (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/1\">",
"      Tryggvason K, Patrakka J. Thin basement membrane nephropathy. J Am Soc Nephrol 2006; 17:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/2\">",
"      Aarons I, Smith PS, Davies RA, et al. Thin membrane nephropathy: a clinico-pathological study. Clin Nephrol 1989; 32:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/3\">",
"      Tiebosch AT, Frederik PM, van Breda Vriesman PJ, et al. Thin-basement-membrane nephropathy in adults with persistent hematuria. N Engl J Med 1989; 320:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/4\">",
"      Thin-membrane nephropathy--how thin is thin? Lancet 1990; 336:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/5\">",
"      Rana K, Wang YY, Powell H, et al. Persistent familial hematuria in children and the locus for thin basement membrane nephropathy. Pediatr Nephrol 2005; 20:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/6\">",
"      Dische FE, Anderson VE, Keane SJ, et al. Incidence of thin membrane nephropathy: morphometric investigation of a population sample. J Clin Pathol 1990; 43:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/7\">",
"      Cosio FG, Falkenhain ME, Sedmak DD. Association of thin glomerular basement membrane with other glomerulopathies. Kidney Int 1994; 46:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/8\">",
"      Savige J, Rana K, Tonna S, et al. Thin basement membrane nephropathy. Kidney Int 2003; 64:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/9\">",
"      Rumpelt HJ. Hereditary nephropathy (Alport syndrome): correlation of clinical data with glomerular basement membrane alterations. Clin Nephrol 1980; 13:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/10\">",
"      Lemmink HH, Nillesen WN, Mochizuki T, et al. Benign familial hematuria due to mutation of the type IV collagen alpha4 gene. J Clin Invest 1996; 98:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/11\">",
"      Buzza M, Wang YY, Dagher H, et al. COL4A4 mutation in thin basement membrane disease previously described in Alport syndrome. Kidney Int 2001; 60:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/12\">",
"      Badenas C, Praga M, Taz&oacute;n B, et al. Mutations in theCOL4A4 and COL4A3 genes cause familial benign hematuria. J Am Soc Nephrol 2002; 13:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/13\">",
"      Buzza M, Dagher H, Wang YY, et al. Mutations in the COL4A4 gene in thin basement membrane disease. Kidney Int 2003; 63:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/14\">",
"      Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/15\">",
"      Frasc&agrave; GM, Onetti-Muda A, Mari F, et al. Thin glomerular basement membrane disease: clinical significance of a morphological diagnosis--a collaborative study of the Italian Renal Immunopathology Group. Nephrol Dial Transplant 2005; 20:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/16\">",
"      Mochizuki T, Lemmink HH, Mariyama M, et al. Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 1994; 8:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/17\">",
"      Boye E, Mollet G, Forestier L, et al. Determination of the genomic structure of the COL4A4 gene and of novel mutations causing autosomal recessive Alport syndrome. Am J Hum Genet 1998; 63:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/18\">",
"      Heidet L, Arrondel C, Forestier L, et al. Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome. J Am Soc Nephrol 2001; 12:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/19\">",
"      Torra R, Taz&oacute;n-Vega B, Ars E, Ballar&iacute;n J. Collagen type IV (alpha3-alpha4) nephropathy: from isolated haematuria to renal failure. Nephrol Dial Transplant 2004; 19:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/20\">",
"      Saito A, Yamazaki H, Nakagawa Y, Arakawa M. Molecular genetics of renal diseases. Intern Med 1997; 36:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/21\">",
"      Kashtan CE. Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 1998; 9:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/22\">",
"      Buzza M, Wilson D, Savige J. Segregation of hematuria in thin basement membrane disease with haplotypes at the loci for Alport syndrome. Kidney Int 2001; 59:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/23\">",
"      Wang YY, Rana K, Tonna S, et al. COL4A3 mutations and their clinical consequences in thin basement membrane nephropathy (TBMN). Kidney Int 2004; 65:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/24\">",
"      Collar JE, Ladva S, Cairns TD, Cattell V. Red cell traverse through thin glomerular basement membranes. Kidney Int 2001; 59:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/25\">",
"      Blumenthal SS, Fritsche C, Lemann J Jr. Establishing the diagnosis of benign familial hematuria. The importance of examining the urine sediment of family members. JAMA 1988; 259:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/26\">",
"      Schurek HJ. Mechanisms of glomerular proteinuria and hematuria. Kidney Int Suppl 1994; 47:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/27\">",
"      Hebert LA, Betts JA, Sedmak DD, et al. Loin pain-hematuria syndrome associated with thin glomerular basement membrane disease and hemorrhage into renal tubules. Kidney Int 1996; 49:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/28\">",
"      Praga M, Mart&iacute;nez MA, Andr&eacute;s A, et al. Association of thin basement membrane nephropathy with hypercalciuria, hyperuricosuria and nephrolithiasis. Kidney Int 1998; 54:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/29\">",
"      Abt AB, Carroll LE, Mohler JH. Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis. Am J Kidney Dis 2000; 35:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/30\">",
"      Auwardt R, Savige J, Wilson D. A comparison of the clinical and laboratory features of thin basement membrane disease (TBMD) and IgA glomerulonephritis (IgA GN). Clin Nephrol 1999; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/31\">",
"      Hall CL, Bradley R, Kerr A, et al. Clinical value of renal biopsy in patients with asymptomatic microscopic hematuria with and without low-grade proteinuria. Clin Nephrol 2004; 62:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/32\">",
"      Pettersson E, T&ouml;rnroth T, Wieslander J. Abnormally thin glomerular basement membrane and the Goodpasture epitope. Clin Nephrol 1990; 33:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/33\">",
"      van Paassen P, van Breda Vriesman PJ, van Rie H, Tervaert JW. Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease-The Limburg Renal Registry. Kidney Int 2004; 66:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/34\">",
"      Iseki K, Miyasato F, Uehara H, et al. Outcome study of renal biopsy patients in Okinawa, Japan. Kidney Int 2004; 66:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/35\">",
"      Nieuwhof CM, de Heer F, de Leeuw P, van Breda Vriesman PJ. Thin GBM nephropathy: premature glomerular obsolescence is associated with hypertension and late onset renal failure. Kidney Int 1997; 51:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/36\">",
"      Yoshioka K, Hino S, Takemura T, et al. Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol 1994; 144:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/37\">",
"      Chrystomou, A, Kincaid-Smith, P, Becker, G. Clinical features and prognosis of thin basement membrane disease (abstract). J Am Soc Nephrol 1993; 4:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/38\">",
"      Knebelmann B, Breillat C, Forestier L, et al. Spectrum of mutations in the COL4A5 collagen gene in X-linked Alport syndrome. Am J Hum Genet 1996; 59:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/39\">",
"      Voskarides K, Damianou L, Neocleous V, et al. COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. J Am Soc Nephrol 2007; 18:3004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/40\">",
"      Kashtan CE. The wages of thin. J Am Soc Nephrol 2007; 18:2800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/41\">",
"      Matsumae T, Fukusaki M, Sakata N, et al. Thin glomerular basement membrane in diabetic patients with urinary abnormalities. Clin Nephrol 1994; 42:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/42\">",
"      Andres A, Praga M, Bello I, et al. Hematuria due to hypercalciuria and hyperuricosuria in adult patients. Kidney Int 1989; 36:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12088/abstract/43\">",
"      Praga M, Alegre R, Hern&aacute;ndez E, et al. Familial microscopic hematuria caused by hypercalciuria and hyperuricosuria. Am J Kidney Dis 2000; 35:141.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3038 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12088=[""].join("\n");
var outline_f11_51_12088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Microscopic hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Gross hematuria and flank pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Other renal manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Indications for renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Distinction from Alport syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3038|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/50/35624\" title=\"diagnostic image 1\">",
"      Thin basement membrane EM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1337?source=related_link\">",
"      Clinical presentation and diagnosis of IgA nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/2/17445?source=related_link\">",
"      Glomerular hematuria: IgA; Alport; thin basement membrane nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/2/35881?source=related_link\">",
"      Loin pain-hematuria syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=related_link\">",
"      Patient information: Glomerular disease overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/7/42106?source=related_link\">",
"      Treatment and prognosis of IgA nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_51_12089="Idiopathic pulmonary hemosiderosis";
var content_f11_51_12089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Idiopathic pulmonary hemosiderosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/51/12089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/51/12089/contributors\">",
"     Nils Milman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/51/12089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/51/12089/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/51/12089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/51/12089/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/51/12089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic pulmonary hemosiderosis is a rare disease found primarily in children that causes recurrent episodes of diffuse alveolar hemorrhage. Recurrent alveolar bleeding may eventually produce pulmonary hemosiderosis and fibrosis. Diffuse alveolar hemorrhage is characterized by hemoptysis, dyspnea, alveolar opacities on chest radiographs, and anemia and can result from a variety of underlying conditions (",
"    <a class=\"graphic graphic_table graphicRef52374 \" href=\"UTD.htm?42/62/44013\">",
"     table 1",
"    </a>",
"    ). When no underlying cause for repeated episodes of diffuse alveolar hemorrhage is apparent, the entity is referred to as idiopathic pulmonary hemosiderosis (IPH) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features, treatment, and prognosis of IPH will be reviewed here. A general discussion of the diffuse alveolar hemorrhage syndromes is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of IPH is unknown. However, the response to immunosuppressive therapy suggests that immune processes may be involved. It appears that a structural defect in the alveolar capillaries, either in the alveolar basement membrane or in the alveolar endothelial cell, may predispose to the condition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The accumulation of neutrophils in the alveoli also may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Immunologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree to which immunologic injury to the lung contributes to the development of IPH remains unclear. Immune complexes have been demonstrated in plasma in several patients; however, immunohistochemical examination of lung tissue generally has",
"    <strong>",
"     not",
"    </strong>",
"    supported an immunologic pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/2,3,7-10\">",
"     2,3,7-10",
"    </a>",
"    ]. The possibility that autoimmune mechanisms play a role in IPH is suggested by the observation that approximately 25 percent of patients with the condition who survive for more than 10 years subsequently develop autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Links between IPH and ingested protein antigens have also been hypothesized, based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulating antibodies against cow's milk have been detected in a number of children with the disorder, suggesting that IPH may be associated with a hypersensitivity reaction to milk [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. However, other investigators have failed to reproduce these findings [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coexistence of celiac disease and IPH, also known as Lane-Hamilton syndrome, has been reported in a large number of cases, and introduction of a gluten-free diet has been associated with remission of pulmonary symptoms in several patients with IPH [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/15-23\">",
"       15-23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"       \"Diagnosis of celiac disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link\">",
"       \"Management of celiac disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Iron metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent hemorrhage can result in the presence of free iron in pulmonary tissue, which can eventually lead to pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The mechanisms involved may be similar to those responsible for the fibrosis in the liver, pancreas, and heart that occurs in hereditary hemochromatosis and other iron overload syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The monocyte-macrophage system, which is involved in processing free iron, displays great heterogeneity between different organs. Alveolar macrophages are less able to degrade erythrocytes and reprocess hemoglobin iron than macrophages in the liver, spleen, and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. It is thought that excess free iron leads to production of oxygen radicals and consequent tissue injury [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/24\">",
"     24",
"    </a>",
"    ]. However, iron induces intense production of intracellular ferritin, which protects the lung macrophages against free iron and oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anemia is observed in IPH due to alveolar hemorrhage and the subsequent accumulation of substantial amounts of iron within alveolar macrophages. The iron stimulates intracellular ferritin production and is initially stored in ferritin molecules, which are then processed into intracellular hemosiderin complexes. The iron in hemosiderin becomes functionally trapped and unavailable for the synthesis of hemoglobin by erythroblasts in the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/24\">",
"     24",
"    </a>",
"    ]. Nevertheless, the iron trapped in intracellular hemosiderin complexes stimulates the macrophages to produce ferritin, which subsequently induces an increase in the serum ferritin level [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contribution of environmental factors to IPH remains speculative. Exposure to second-hand smoke and indoor molds, particularly Stachybotrys chartarum, has been suggested as a causative factor in infants with IPH [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Neither of these associations has been confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In advanced cases of IPH, the lungs have a striking brown appearance due to hemosiderosis and varying degrees of consolidation and fibrosis. Light microscopy demonstrates alveoli containing numerous hemosiderin-laden macrophages as a characteristic but nonspecific finding. Thickening of alveolar walls is generally present and type II pneumocytes are increased in number. Localized interstitial fibrosis with collagen deposition is a prominent feature in patients with long-standing disease (",
"    <a class=\"graphic graphic_picture graphicRef60870 graphicRef78396 graphicRef79610 \" href=\"UTD.htm?35/54/36714\">",
"     picture 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/2-4,8,10,15\">",
"     2-4,8,10,15",
"    </a>",
"    ]. Erythrocytes can be seen in the alveoli following recent bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A key feature of IPH is the absence of histological or immunohistochemical evidence of capillaritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In particular, infiltration with neutrophils and nuclear dust in the alveolar septa are not seen.",
"   </p>",
"   <p>",
"    Electron microscopy demonstrates swollen, vacuolated alveolar endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/2\">",
"     2",
"    </a>",
"    ]. The basement membrane of the alveolar capillaries may be focally thickened; localized discontinuities with rupture of the membrane have also been inconsistently described [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/2,3,5,10\">",
"     2,3,5,10",
"    </a>",
"    ]. Absence of electron-dense material along the basement membrane is evidence against immune complex deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence and prevalence of IPH are largely unknown. The estimated yearly incidence among Swedish children from 1960 through 1979 was 0.24 per 1,000,000 children [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/35\">",
"     35",
"    </a>",
"    ]. A retrospective review of records from a tertiary pediatric hospital in northern Taiwan noted 5 cases over 25 years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/36\">",
"     36",
"    </a>",
"    ]. There is no definite predilection for gender.",
"   </p>",
"   <p>",
"    Eighty percent of cases of IPH occur in children, generally manifesting before 10 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In adults, most cases are recognized before 30 years of age. Familial clustering has been described in several reports [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/12,39,40\">",
"     12,39,40",
"    </a>",
"    ], suggesting that hereditary factors play a role in the development of IPH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    that environmental factors might precipitate the disease in genetically predisposed individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older series of IPH probably included many patients who would not currently be considered to fit diagnostic criteria of the syndrome, including patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (such as granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyarteritis nodosa) and other collagen vascular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/1\">",
"     1",
"    </a>",
"    ]. Sensitive assays for detection of autoimmune antibodies, new scintigraphic methods, and less invasive techniques for lung biopsy have permitted a more refined classification of patients with diffuse alveolar hemorrhage that were not available when early series were performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of IPH varies from an acute onset illness with hemoptysis and dyspnea to an insidious process characterized by fatigue, anemia, and slowly progressive exertional dyspnea. In some cases, anemia is the sole presenting sign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPH often begins in children with recurrent episodes of dyspnea and cough. Initially, the cough is predominantly nonproductive. Hemoptysis, occasionally with large amounts of expectorated blood, occurs later. Eventually, children develop moderate to severe anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In adults, the most frequent symptoms are exertional dyspnea and fatigue due to pulmonary hemorrhage and iron deficiency anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8\">",
"     8",
"    </a>",
"    ]. Nearly all adult patients develop hemoptysis, which may range from occasional blood-streaked sputum to daily significant hemoptysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8,12,39\">",
"     8,12,39",
"    </a>",
"    ]. In children, failure to thrive and anemia may be the presenting findings and hemoptysis is less common [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/1,42\">",
"     1,42",
"    </a>",
"    ]. Rapid asphyxiation due to massive pulmonary hemorrhage has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children may fail to thrive and appear pale and anemic. Cough and dyspnea at rest or with exertion may be prominent. Lung examination may reveal clear lungs or crackles [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 20 percent have enlargement of the liver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency anemia, which can range from mild to severe, is generally the sole laboratory abnormality in patients with IPH. Presence of coagulopathy, thrombocytopenia, hepatic dysfunction, or glomerulonephritis would suggest an alternate diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutropenia and eosinophilia have been reported 5 to 10 days before the onset of alveolar hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/6\">",
"     6",
"    </a>",
"    ]. Bone marrow biopsy typically shows hyperplastic erythropoiesis, usually without stainable hemosiderin iron [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8,37\">",
"     8,37",
"    </a>",
"    ]. Estimation of the mean erythrocyte survival time using chromium-51-labeled autologous erythrocytes shows a reduced survival time due to deposition of erythrocytes in the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8\">",
"     8",
"    </a>",
"    ]. Plasma bilirubin and urinary excretion of urobilinogen may be increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several caveats apply to approaching anemia in patients with IPH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following a bleeding episode, a high number of reticulocytes may be present in the blood, mimicking hemolytic anemia. However, specific tests for hemolysis are negative [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=see_link\">",
"       \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since hemorrhagic sputum is often swallowed, children often present with a positive test for fecal occult blood. This can result in an exhaustive search for a source of gastrointestinal bleeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=see_link\">",
"       \"Evaluation of occult gastrointestinal bleeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum ferritin concentrations, which in healthy subjects reflect mobilizable body iron stores, may be misleading in IPH because they apparently also reflect the nonmobilizable hemosiderin iron located in the lungs [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Cases of IPH with normal serum ferritin despite iron deficiency anemia have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8,42\">",
"       8,42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following an acute episode with pulmonary bleeding, chest radiographs demonstrate opacities that subsequently can regress during the symptom-free phase (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62374 \" href=\"UTD.htm?21/13/21716\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50621 \" href=\"UTD.htm?11/18/11553\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8,37\">",
"     8,37",
"    </a>",
"    ]. These opacities have ground-glass characteristics on high resolution computed tomography (HRCT) scan. Unilateral or bilateral poorly defined opacities with an alveolar filling pattern are most prominent in the middle and lower lung fields. The opacities vary in intensity according to the magnitude of alveolar bleeding and the period of time elapsed since the latest bleeding episode. Patients with long-standing disease may occasionally develop multiple honeycomb cysts, which are characteristically focal and localized predominantly to the posterior and lateral basal segments [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ventilation-perfusion scanning, normally used to aid in the diagnosis of pulmonary emboli, also can be employed to demonstrate intrapulmonary bleeding. In cases of ongoing pulmonary hemorrhage, perfusion scanning with 99mTc-labeled albumin particles (diameter 15 to 25 mcg) reveals foci of high radioactivity in the lungs where radioactively tagged material has extravasated into the alveoli.",
"   </p>",
"   <p>",
"    Alternatively, ongoing intrapulmonary bleeding can be visualized by pulmonary radioscintigraphy, in which autologous erythrocytes labeled with 51Cr or 99mTc are injected intravenously with subsequent recording of the radioactivity over the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/46\">",
"     46",
"    </a>",
"    ]. However, bronchoalveolar lavage has largely replaced use of nuclear scans for diagnosis of pulmonary bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing shows restrictive abnormalities, with reductions in TLC, FVC, and a normal or increased",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8,47\">",
"     8,47",
"    </a>",
"    ]. Varying degrees of hypoxemia with eucapnia or hypocapnia occur, and frequently worsen with exercise.",
"   </p>",
"   <p>",
"    During an acute bleeding episode, hemoglobin in erythrocytes that have spilled into the alveoli avidly bind carbon monoxide, thereby producing an inappropriately high DLCO [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/48\">",
"     48",
"    </a>",
"    ]. When the intraalveolar erythrocytes and the hemoglobin they contain are degraded, the DLCO declines to prehemorrhage levels, and may be chronically reduced in cases in which parenchymal fibrosis has developed. While theoretically helpful, measurement of DLCO in the setting of acute hemoptysis is often not feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sputum examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical suspicion of alveolar hemorrhage can be substantiated by examination of a representative sputum sample containing alveolar macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/49\">",
"     49",
"    </a>",
"    ]. Prussian blue staining for iron demonstrates the presence of hemosiderin-laden alveolar macrophages. However, this test does not appear to be highly sensitive, and a negative result should not preclude further work-up if indicated clinically. In addition, bronchoalveolar lavage is usually needed to evaluate other causes of DAH, such as infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchoalveolar lavage (BAL) is usually performed in segments of the lung where HRCT shows ground-glass opacification, or in the right middle lobe if disease is diffuse. Three sequential instillations are performed at the same site; observation of progressively more hemorrhagic fluid with each successive lavage suggests alveolar hemorrhage. Differential cell counts of BAL fluid show a predominance of alveolar macrophages, typically containing hemosiderin (",
"    <a class=\"graphic graphic_picture graphicRef52119 \" href=\"UTD.htm?33/36/34370\">",
"     picture 2",
"    </a>",
"    ). Lavage fluid is sent for culture to exclude infectious etiologies and cytologic analysis to quantitate hemosiderin-laden macrophages and look for viral inclusion bodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no feature that is pathognomonic of IPH. As a result, the diagnosis relies on exclusion of other disorders in which diffuse alveolar hemorrhage is a cardinal sign (",
"    <a class=\"graphic graphic_table graphicRef52374 \" href=\"UTD.htm?42/62/44013\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/1,50\">",
"     1,50",
"    </a>",
"    ]. The diagnosis is supported by the combination of compatible clinical findings (eg, hemoptysis, cough, dyspnea), compatible laboratory findings (eg, opacities on chest radiograph, iron deficiency anemia), and the finding of hemosiderin-laden alveolar macrophages on BAL and lung biopsy specimens.",
"   </p>",
"   <p>",
"    Our diagnostic approach is outlined in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef80333 \" href=\"UTD.htm?5/8/5248\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should have their anemia classified by appropriate laboratory tests, which may reveal an iron deficiency anemia (",
"      <a class=\"graphic graphic_table graphicRef76236 \" href=\"UTD.htm?32/58/33708\">",
"       table 2",
"      </a>",
"      ). Examination for occult bleeding from the gastrointestinal, urinary, or genital tract should be performed.",
"     </li>",
"     <li>",
"      Screening for coagulopathy and autoimmune disorders should be part of the routine evaluation, and there should be no evidence of autoimmune disease, such as antinuclear antibodies (ANA), antidouble-stranded DNA (anti-dsDNA), antineutrophil cytoplasmic antibodies (ANCA), antiglomerular basement membrane (GBM) antibodies, antiphospholipid antibodies, or rheumatoid factor (",
"      <a class=\"graphic graphic_table graphicRef57788 \" href=\"UTD.htm?9/31/9725\">",
"       table 3",
"      </a>",
"      ). Patients should also be screened for celiac disease with serologic tests for IgA anti tissue transglutaminase and endomysial antibodies. Patients should also be tested for antibodies against cow's milk (IgG and IgE). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"       \"Diagnosis of celiac disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=see_link\">",
"       \"The diffuse alveolar hemorrhage syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High resolution chest computed tomography (HRCT) should be performed. Typical findings include ground glass opacities that may be diffuse or patchy. The location of opacities on HRCT is often used to guide the choice of sites for BAL and transbronchial or open lung biopsy.",
"     </li>",
"     <li>",
"      BAL should be performed in areas of apparent radiographic involvement, or if diffuse involvement, a dependent lobe (eg, the right middle lobe). Hemosiderin-laden alveolar macrophages are always present in BAL fluid in IPH and also may be found in the sputum. They confirm the presence of alveolar hemorrhage but cannot be used as the sole diagnostic criterion for IPH.",
"     </li>",
"     <li>",
"      In children with a clinical presentation, laboratory and BAL findings, and HRCT pattern that are typical for IPH and negative serology for immune mediated diseases, lung biopsy is rarely needed [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In adults, lung biopsy is needed to confirm the diagnosis of IPH. Transbronchial lung biopsy has a reasonable yield for providing supportive pathologic data, and should be the biopsy procedure of first choice in stable adults. Four to eight transbronchial biopsy specimens should be obtained from one lung, preferably taken in segments showing ground-glass opacification. If a diagnosis cannot be made on these relatively small biopsy specimens, larger samples should be obtained by video assisted thoracoscopic surgery (VATS) or open lung biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=see_link\">",
"       \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lung biopsies should not reveal any other specific pathology, such as granulomas indicating mycobacterial infection, sarcoidosis, or granulomatosis with polyangiitis (Wegener&rsquo;s); evidence of",
"    <span class=\"nowrap\">",
"     vasculitis/capillaritis;",
"    </span>",
"    evidence of specific deposition of immunoglobulins; or evidence of pulmonary infarction or other infections. In addition to light microscopy, biopsy specimens, preferably frozen, should be examined with immunofluorescence-technique using a panel of antibodies against immunoglobulins and complement fractions in order to search for immune complexes. The finding of immune complex deposition would argue against the diagnosis of IPH.",
"   </p>",
"   <p>",
"    At the time of initial presentation and recurrent episodes of alveolar hemorrhage, infectious causes need to be excluded (",
"    <a class=\"graphic graphic_table graphicRef52374 \" href=\"UTD.htm?42/62/44013\">",
"     table 1",
"    </a>",
"    ). This is best accomplished with a combination of blood culture, BAL stain and culture, cytologic analysis of bronchial brush and lavage samples, serologic studies of blood and urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=see_link&amp;anchor=H18#H18\">",
"     \"Basic principles and technique of bronchoalveolar lavage\", section on 'Microbiologic analysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medications and inhalational exposures that may cause alveolar hemorrhage (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    , crack cocaine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/22/25958?source=see_link\">",
"     nitrofurantoin",
"    </a>",
"    , trimellitic anhydride) should also be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;IPH is a rare condition that does not lend itself to controlled treatment trials. As a result, therapy is based upon reported experiences in individual cases or small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8,37,52-54\">",
"     8,37,52-54",
"    </a>",
"    ]. For patients with evidence of concomitant celiac disease, a gluten-free diet is recommended, based on reports of clinical remission during gluten avoidance [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/12,15-22,27\">",
"     12,15-22,27",
"    </a>",
"    ]. For most others, systemic glucocorticoids are the mainstay of therapy, although some patients require additional immunosuppressive agents.",
"   </p>",
"   <p>",
"    The most useful parameters to follow for assessing whether a patient is having a beneficial response to therapy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decrease in frequency or intensity of hemoptysis",
"     </li>",
"     <li>",
"      Regression of iron deficiency anemia",
"     </li>",
"     <li>",
"      Regression of opacifications on chest radiograph",
"     </li>",
"     <li>",
"      Improving oxygen saturation",
"     </li>",
"     <li>",
"      Normalization of DLCO",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of systemic glucocorticoids for IPH grew out of the impression of an immune pathogenesis. Although data are sparse, case reports and case series suggest that systemic glucocorticoids reduce the morbidity and mortality of acute episodes of alveolar bleeding and control progression of pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/1,8,10,37,52-55\">",
"     1,8,10,37,52-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Acute alveolar hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the treatment of acute episodes of alveolar hemorrhage related to IPH, we suggest initial doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    of 0.5 to 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Induction treatment should continue until pulmonary bleeding has stopped and the chest radiograph shows regression of newly acquired opacifications, which usually requires one to two months. At this point, prednisolone should be tapered by 5 mg every other week to a maintenance dose of 10 to 15",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    For",
"    patients with respiratory failure due to severe alveolar hemorrhage, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, administered intravenously [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of supportive care and airway management for patients with massive hemoptysis is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=see_link\">",
"     \"Massive hemoptysis: Initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Chronic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with IPH appear to respond favorably to chronic oral glucocorticoids, with decreased frequency of episodes of acute alveolar hemorrhage and a delay in or arrest of fibrotic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8,10,53,55\">",
"     8,10,53,55",
"    </a>",
"    ]. In a series of 23 children with IPH, low dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was associated with prolonged survival (one death in 2 to 14 years of monitoring) compared to historical controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/37,53\">",
"     37,53",
"    </a>",
"    ]. In another series of 17 patients, long-term glucocorticoid therapy was associated with a five-year Kaplan-Meier survival of 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/55\">",
"     55",
"    </a>",
"    ]. Treatment may be discontinued after 18 to 24 months if the patient has been free of recurrent events.",
"   </p>",
"   <p>",
"    In a small number of cases, high dose inhaled glucocorticoids have appeared beneficial when systemic treatment was not tolerated or as adjunctive therapy to oral glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/51,56,57\">",
"     51,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During chronic glucocorticoid therapy, patients should be monitored appropriately for side effects. Infectious complications, including Legionella pneumonia and fatal invasive pulmonary aspergillosis, have been reported in patients with IPH receiving glucocorticoids or other immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Immunosuppressive drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;An immunosuppressive agent may be added to oral glucocorticoid therapy in patients who have severe initial disease or have recurrent episodes of alveolar hemorrhage that limit tapering of oral glucocorticoids. However, evidence supporting the efficacy of this approach is limited.",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    have been used successfully in combination with oral glucocorticoids in a number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/1,4,36,51,60-62\">",
"     1,4,36,51,60-62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other immunosuppressive drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or 6-mercaptopurine, are occasionally employed in patients with an inadequate response to glucocorticoids, but their efficacy is also not well established [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Extracorporeal membrane oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal membrane oxygenation (ECMO) may be able to support the rare patient who develops intractable hypoxemia due to acute IPH. In one child with IPH and respiratory failure due to severe pulmonary hemorrhage, ECMO provided oxygenation until immunosuppressive therapy controlled the hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/66\">",
"     66",
"    </a>",
"    ]. The utility of ECMO in adults with DAH is unknown. The use of ECMO is limited to centers with specialized expertise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=see_link\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single lung transplantation has been reported, but disease recurrence within the allograft appears to be a problem [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. In one report, a 24-year-old woman with pulmonary insufficiency due to IPH developed graft failure of the single left lung allograft, and retransplantation was performed after nine months [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/67\">",
"     67",
"    </a>",
"    ]. The patient succumbed to respiratory failure three months after the second transplantation. Autopsy showed no evidence of infection or rejection, but did reveal findings compatible with IPH in the transplanted lungs. In another report, IPH recurred three years after bilateral lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of IPH is difficult to assess because of the small series of patients, short observation times, and inadequate follow-up. The two most frequent causes of death are copious pulmonary hemorrhage with acute respiratory failure, or chronic respiratory failure due to pulmonary hemosiderosis and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/6,37,52\">",
"     6,37,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival time displays wide variation. As an example, one series of 68 patients with a mean duration of active disease of approximately four years found that 20 patients died, 17 had recurrent episodes of pulmonary hemorrhage, 12 had chronic active disease with persisting dyspnea and anemia, and 19 appeared healthy and without symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/37\">",
"     37",
"    </a>",
"    ]. In contrast, a different series of 17 pediatric patients documented a better prognosis, with a five-year survival rate of 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears that children and adolescents more frequently experience a rapid course and have a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/37\">",
"     37",
"    </a>",
"    ]. In adults, the course is often prolonged, symptoms are less pronounced, and the prognosis is more favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12089/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic pulmonary hemosiderosis (IPH) is a rare clinical entity of unknown etiology, characterized by recurrent episodes of diffuse alveolar hemorrhage and often presenting with hemoptysis. Many patients develop iron deficiency anemia due to sequestration of red cell hemoglobin iron to hemosiderin iron in the alveoli. After recurrent episodes of hemorrhage, pulmonary fibrosis may develop due to iron accumulation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During an acute episode, the chest radiograph and high resolution computed tomography demonstrate ground glass alveolar opacities that are often bilateral. Examination of sputum and bronchoalveolar lavage (BAL) fluid reveals hemosiderin-laden alveolar macrophages, but the final diagnosis requires lung biopsy documentation of large numbers of hemosiderin-laden macrophages in the alveoli, without evidence of vasculitis, capillaritis, inflammation, granulomas, or deposition of immunoglobulins in any specific pattern. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A gluten-free diet may improve pulmonary hemosiderosis in patients with co-existent celiac disease and pulmonary hemosiderosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Immunologic abnormalities'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link\">",
"       \"Management of celiac disease in adults\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of acute episodes of alveolar hemorrhage related to IPH, we suggest systemic glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The typical dose is oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      of 0.5 to 0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, or the equivalent dose intravenously. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have severe initial disease or have recurrent episodes of alveolar hemorrhage that limit tapering of systemic glucocorticoid, we suggest using a combination of systemic glucocorticoids with another immunosuppressive agent (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , 6-mercaptopurine, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Immunosuppressive drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/1\">",
"      Ioachimescu OC, Sieber S, Kotch A. Idiopathic pulmonary haemosiderosis revisited. Eur Respir J 2004; 24:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/2\">",
"      Corrin B, Jagusch M, Dewar A, et al. Fine structural changes in idiopathic pulmonary haemosiderosis. J Pathol 1987; 153:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/3\">",
"      Donald KJ, Edwards RL, McEvoy JD. Alveolar capillary basement membrane lesions in Goodpasture's syndrome and idiopathic pulmonary hemosiderosis. Am J Med 1975; 59:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/4\">",
"      Yeager H Jr, Powell D, Weinberg RM, et al. Idiopathic pulmonary hemosiderosis: ultrastructural studies and responses to azathioprine. Arch Intern Med 1976; 136:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/5\">",
"      Hyatt RW, Adelstein ER, Halazun JF, Lukens JN. Ultrastructure of the lung in idiopthic pulmonary hemosiderosis. Am J Med 1972; 52:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/6\">",
"      Cohen S. Idiopathic pulmonary hemosiderosis. Am J Med Sci 1999; 317:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/7\">",
"      Blanco A, Sol&iacute;s P, G&oacute;mez S, et al. C1q-binding immune complexes and other immunological studies in children with pulmonary hemosiderosis. Allergol Immunopathol (Madr) 1984; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/8\">",
"      Ali, AM, Milman, N, Clausen, PP, et al. Idiopathic pulmonary haemosiderosis. Favourable effect of corticosteroids in two women aged 16 and 55 years. Eur Respir Topic 1998; 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/9\">",
"      Dolan CJ Jr, Srodes CH, Duffy FD. Idiopathic pulmonary hemosiderosis. Electron microscopic, immunofluorescent, and iron kinetic studies. Chest 1975; 68:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/10\">",
"      Irwin RS, Cottrell TS, Hsu KC, et al. Idiopathic pulmonary hemosiderosis: an electron microscopic and immunofluorescent study. Chest 1974; 65:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/11\">",
"      Le Clainche L, Le Bourgeois M, Fauroux B, et al. Long-term outcome of idiopathic pulmonary hemosiderosis in children. Medicine (Baltimore) 2000; 79:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/12\">",
"      Milman N, Pedersen FM. Idiopathic pulmonary haemosiderosis. Epidemiology, pathogenic aspects and diagnosis. Respir Med 1998; 92:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/13\">",
"      Boat TF, Polmar SH, Whitman V, et al. Hyperreactivity to cow milk in young children with pulmonary hemosiderosis and cor pulmonale secondary to nasopharyngeal obstruction. J Pediatr 1975; 87:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/14\">",
"      Torres MJ, Gir&oacute;n MD, Corzo JL, et al. Release of inflammatory mediators after cow's milk intake in a newborn with idiopathic pulmonary hemosiderosis. J Allergy Clin Immunol 1996; 98:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/15\">",
"      Wright PH, Menzies IS, Pounder RE, Keeling PW. Adult idiopathic pulmonary haemosiderosis and coeliac disease. Q J Med 1981; 50:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/16\">",
"      Pacheco A, Casanova C, Fogue L, Sueiro A. Long-term clinical follow-up of adult idiopathic pulmonary hemosiderosis and celiac disease. Chest 1991; 99:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/17\">",
"      Hemoptysis, pulmonary infiltrates, and diarrhea in a 36-year-old man. Am J Med 1986; 80:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/18\">",
"      Reading R, Watson JG, Platt JW, Bird AG. Pulmonary haemosiderosis and gluten. Arch Dis Child 1987; 62:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/19\">",
"      Bouros D, Panagou P, Rokkas T, Siafakas NM. Bronchoalveolar lavage findings in a young adult with idiopathic pulmonary haemosiderosis and coeliac disease. Eur Respir J 1994; 7:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/20\">",
"      Agarwal R, Aggarwal AN, Gupta D. Lane-Hamilton syndrome: simultaneous occurrence of coeliac disease and idiopathic pulmonary haemosiderosis. Intern Med J 2007; 37:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/21\">",
"      Khemiri M, Ouederni M, Khaldi F, Barsaoui S. Screening for celiac disease in idiopathic pulmonary hemosiderosis. Gastroenterol Clin Biol 2008; 32:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/22\">",
"      Lane DJ, Hamilton WS. Idiopathic steatorrhoea and idiopathic pulmonary haemosiderosis. Br Med J 1971; 2:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/23\">",
"      Sethi GR, Singhal KK, Puri AS, Mantan M. Benefit of gluten-free diet in idiopathic pulmonary hemosiderosis in association with celiac disease. Pediatr Pulmonol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/24\">",
"      Custer G, Balcerzak S, Rinehart J. Human macrophage hemoglobin-iron metabolism in vitro. Am J Hematol 1982; 13:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/25\">",
"      DeGowin RL, Sorensen LB, Charleston DB, et al. Retention of radioiron in the lungs of a woman with idiopathic pulmonary hemosiderosis. Ann Intern Med 1968; 69:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/26\">",
"      Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron metabolism in humans: abnormal behavior in idiopathic hemochromatosis and in inflammation. Blood 1989; 74:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/27\">",
"      Persson HL, Vainikka LK, Eriksson HB, Wennerstr&ouml;m U. Lane-Hamilton syndrome: ferritin protects lung macrophages against iron and oxidation. Chest 2011; 139:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/28\">",
"      Dearborn DG, Yike I, Sorenson WG, et al. Overview of investigations into pulmonary hemorrhage among infants in Cleveland, Ohio. Environ Health Perspect 1999; 107 Suppl 3:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/29\">",
"      Hossain MA, Ahmed MS, Ghannoum MA. Attributes of Stachybotrys chartarum and its association with human disease. J Allergy Clin Immunol 2004; 113:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/30\">",
"      Brown CM, Redd SC, Damon SA, Centers for Disease Control and Prevention (CDC). Acute idiopathic pulmonary hemorrhage among infants. Recommendations from the Working Group for Investigation and Surveillance. MMWR Recomm Rep 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/31\">",
"      Dearborn DG, Smith PG, Dahms BB, et al. Clinical profile of 30 infants with acute pulmonary hemorrhage in Cleveland. Pediatrics 2002; 110:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/32\">",
"      Soergel, KH, Sommers, SC. The alveolar epithelial lesion of idiopathic pulmonary hemosiderosis. Am Rev Respir Dis 1962; 85:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/33\">",
"      Green RJ, Ruoss SJ, Kraft SA, et al. Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management. Chest 1996; 110:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/34\">",
"      Jennings CA, King TE Jr, Tuder R, et al. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. Am J Respir Crit Care Med 1997; 155:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/35\">",
"      Kjellman B, Elinder G, Garwicz S, Svan H. Idiopathic pulmonary haemosiderosis in Swedish children. Acta Paediatr Scand 1984; 73:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/36\">",
"      Yao TC, Hung IJ, Wong KS, et al. Idiopathic pulmonary haemosiderosis: an Oriental experience. J Paediatr Child Health 2003; 39:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/37\">",
"      Soergel, KH, Sommers, SC. Idiopathic pulmonary hemosiderosis and related syndromes. Am J Med 1962; 32:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/38\">",
"      Morgan PG, Turner-Warwick M. Pulmonary haemosiderosis and pulmonary haemorrhage. Br J Dis Chest 1981; 75:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/39\">",
"      Beckerman RC, Taussig LM, Pinnas JL. Familial idiopathic pulmonary hemosiderosis. Am J Dis Child 1979; 133:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/40\">",
"      Thaell JF, Greipp PR, Stubbs SE, Siegal GP. Idiopathic pulmonary hemosiderosis: two cases in a family. Mayo Clin Proc 1978; 53:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/41\">",
"      Cassimos CD, Chryssanthopoulos C, Panagiotidou C. Epidemiologic observations in idiopathic pulmonary hemosiderosis. J Pediatr 1983; 102:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/42\">",
"      Chen RL, Chuang SS. Silent idiopathic pulmonary hemosiderosis with iron-deficiency anemia but normal serum ferritin. J Pediatr Hematol Oncol 2007; 29:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/43\">",
"      Walters GO, Miller FM, Worwood M. Serum ferritin concentration and iron stores in normal subjects. J Clin Pathol 1973; 26:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/44\">",
"      Milman N, Pedersen NS, Visfeldt J. Serum ferritin in healthy Danes: relation to marrow haemosiderin iron stores. Dan Med Bull 1983; 30:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/45\">",
"      Harte S, McNicholas WT, Donnelly SC, Dodd JD. Honeycomb cysts in idiopathic pulmonary haemosiderosis: high-resolution CT appearances in two adults. Br J Radiol 2008; 81:e295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/46\">",
"      Miller T, Tanaka T. Nuclear scan of pulmonary hemorrhage in idiopathic pulmonary hemosiderosis. AJR Am J Roentgenol 1979; 132:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/47\">",
"      Allue X, Wise MB, Beaudry PH. Pulmonary function studies in idiopathic pulmonary hemosiderosis in children. Am Rev Respir Dis 1973; 107:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/48\">",
"      Ewan PW, Jones HA, Rhodes CG, Hughes JM. Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture's syndrome. N Engl J Med 1976; 295:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/49\">",
"      Kocakoc E, Kiris A, Sen Y, Bozgeyik Z. Pediatric idiopathic pulmonary hemosiderosis diagnosed by sputum analysis: plain radiography and computed tomography findings. Med Princ Pract 2003; 12:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/50\">",
"      Yao TC, Hung IJ, Jaing TH, Yang CP. Pitfalls in the diagnosis of idiopathic pulmonary haemosiderosis. Arch Dis Child 2002; 86:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/51\">",
"      Kabra SK, Bhargava S, Lodha R, et al. Idiopathic pulmonary hemosiderosis: clinical profile and follow up of 26 children. Indian Pediatr 2007; 44:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/52\">",
"      Nielsen VR, Valerius NH. [Idiopathic pulmonary hemosiderosis. A cause of severe iron deficiency anemia in childhood]. Ugeskr Laeger 1995; 157:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/53\">",
"      Kiper N, G&ouml;&ccedil;men A, Oz&ccedil;elik U, et al. Long-term clinical course of patients with idiopathic pulmonary hemosiderosis (1979-1994): prolonged survival with low-dose corticosteroid therapy. Pediatr Pulmonol 1999; 27:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/54\">",
"      Ohga S, Nomura A, Suga N, et al. Liposteroid against refractory pulmonary haemorrhage in idiopathic pulmonary haemosiderosis. Eur J Pediatr 1994; 153:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/55\">",
"      Saeed MM, Woo MS, MacLaughlin EF, et al. Prognosis in pediatric idiopathic pulmonary hemosiderosis. Chest 1999; 116:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/56\">",
"      Elinder G. Budesonide inhalation to treat idiopathic pulmonary haemosiderosis. Lancet 1985; 1:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/57\">",
"      Tutor JD, Eid NS. Treatment of idiopathic pulmonary hemosiderosis with inhaled flunisolide. South Med J 1995; 88:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/58\">",
"      Watson AM, Boyce TG, Wylam ME. Legionella pneumonia: infection during immunosuppressive therapy for idiopathic pulmonary hemosiderosis. Pediatr Infect Dis J 2004; 23:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/59\">",
"      Helman DL, Sullivan A, Kariya ST, et al. Management of idiopathic pulmonary haemosiderosis in pregnancy: report of two cases. Respirology 2003; 8:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/60\">",
"      Rossi GA, Balzano E, Battistini E, et al. Long-term prednisone and azathioprine treatment of a patient with idiopathic pulmonary hemosiderosis. Pediatr Pulmonol 1992; 13:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/61\">",
"      Byrd RB, Gracey DR. Immunosuppressive treatment of idiopathic pulmonary hemosiderosis. JAMA 1973; 226:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/62\">",
"      Airaghi L, Ciceri L, Giannini S, et al. Idiopathic pulmonary hemosiderosis in an adult. Favourable response to azathioprine. Monaldi Arch Chest Dis 2001; 56:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/63\">",
"      Huang SH, Lee PY, Niu CK. Treatment of pediatric idiopathic pulmonary hemosiderosis with low-dose cyclophosphamide. Ann Pharmacother 2003; 37:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/64\">",
"      Naithani R, Chandra J, Singh V, et al. Life threatening exacerbation in idiopathic pulmonary hemosiderosis salvaged by cyclophosphamide infusion. Indian J Chest Dis Allied Sci 2006; 48:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/65\">",
"      Luo XQ, Ke ZY, Huang LB, et al. Maintenance therapy with dose-adjusted 6-mercaptopurine in idiopathic pulmonary hemosiderosis. Pediatr Pulmonol 2008; 43:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/66\">",
"      Sun LC, Tseng YR, Huang SC, et al. Extracorporeal membrane oxygenation to rescue profound pulmonary hemorrhage due to idiopathic pulmonary hemosiderosis in a child. Pediatr Pulmonol 2006; 41:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/67\">",
"      Wroblewski BM, Stefanovic CR, McDonough VM, Kidik PJ. The challenges of idiopathic pulmonary hemosiderosis and lung transplantation. Crit Care Nurse 1997; 17:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12089/abstract/68\">",
"      Calabrese F, Giacometti C, Rea F, et al. Recurrence of idiopathic pulmonary hemosiderosis in a young adult patient after bilateral single-lung transplantation. Transplantation 2002; 74:1643.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4318 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12089=[""].join("\n");
var outline_f11_51_12089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Immunologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Iron metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other associations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sputum examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Acute alveolar hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Immunosuppressive drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Extracorporeal membrane oxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4318\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4318|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?5/8/5248\" title=\"algorithm 1\">",
"      Algorithm for diagnosis of IPH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4318|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/13/21716\" title=\"diagnostic image 1\">",
"      Idiopathic hemosiderosis PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?11/18/11553\" title=\"diagnostic image 2\">",
"      Idiopathic hemosiderosis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4318|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/19/16692\" title=\"picture 1A\">",
"      IPH macrophages High",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/56/14214\" title=\"picture 1B\">",
"      Type II hyperplasia in IPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/43/14006\" title=\"picture 1C\">",
"      Cytokeratin 7 in IPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/36/34370\" title=\"picture 2\">",
"      IPH alveolar macrophages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4318|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/62/44013\" title=\"table 1\">",
"      Causes of DAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/58/33708\" title=\"table 2\">",
"      Lab tests in iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/31/9725\" title=\"table 3\">",
"      Diagnostic studies in IPH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11336?source=related_link\">",
"      Evaluation of occult gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30454?source=related_link\">",
"      Massive hemoptysis: Initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_51_12090="Pathogenesis of spondyloarthritis";
var content_f11_51_12090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of spondyloarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/51/12090/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/51/12090/contributors\">",
"     David T Yu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/51/12090/contributors\">",
"     Astrid van Tubergen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/51/12090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/51/12090/contributors\">",
"     Joachim Sieper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/51/12090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/51/12090/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/51/12090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term spondyloarthritis (SpA, formerly spondyloarthropathy) is used to refer to a group of disorders that includes ankylosing spondylitis (AS), undifferentiated spondyloarthritis, reactive arthritis (ReA), and the arthritis and spondylitis that may accompany psoriasis and inflammatory bowel diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"     \"Arthritis associated with gastrointestinal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This section will focus primarily on AS, regarding which the most is known. The pathogeneses of the other members of the spondyloarthritis family are closely related to that of AS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical manifestations, diagnosis, and treatment of AS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=see_link\">",
"     \"Diagnosis and differential diagnosis of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Likewise, a discussion of the clinical aspects of the other types of spondyloarthritis is presented in detail elsewhere. (See appropriate topic reviews.)",
"   </p>",
"   <p>",
"    Disease in childhood is presented from a pediatric standpoint, also separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=see_link\">",
"     \"Spondyloarthropathy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     KEY OBSERVATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several key observations that form the basis for our understanding of the pathogenesis of ankylosing spondylitis (AS) and for evolving hypotheses regarding the disease mechanisms underlying spondyloarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The entheses are a major site for the pathology of AS. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology of AS'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Genetic factors are highly important in susceptibility to AS. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetic influences'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Human leukocyte antigen (HLA)-B27 is an important disease-associated gene. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Disease association with HLA-B27'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Tumor necrosis factor (TNF)-alpha is one of the cytokines mediating AS. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cytokines'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      AS involves new bone formation. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Osteoimmunology: Bone erosion and new bone formation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Increased levels of interleukin (IL)-23 and entheseal IL-23 responsive T cells may be important in inflammation and bone remodeling. (See",
"      <a class=\"local\" href=\"#H427628909\">",
"       'Entheseal IL-23 responsive T cells'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathology of AS",
"    </span>",
"    &nbsp;&mdash;&nbsp;John Ball was the first to report that the pathological feature that distinguished AS from rheumatoid arthritis was that the major involvement in AS was at the entheses and not at the synovia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/3\">",
"     3",
"    </a>",
"    ]. Entheses are located where ligaments, tendons, and joint capsules are attached to bone. At the vertebrae, the entheses are at the annulus fibrosus. Two processes are observed. One is bone destruction, and the other is new bone formation, which can occur in the sacroiliac joints, the vertebrae (syndesmophyte formation), and other entheseal sites. When the syndesmophytes bridge across all the vertebrae, the spine becomes the classical, but very uncommon, bamboo spine of AS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunochemistry shows the presence of bone-destructive cathepsin-K and metalloproteinase 1 in the osteoclasts at the enthesitis areas of the vertebrae [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/4\">",
"     4",
"    </a>",
"    ]. Immunohistology shows T cells, B cells, bone marrow macrophages, and cells involved in neoangiogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H427628909\">",
"     'Entheseal IL-23 responsive T cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Enthesitis also involves the extremities. The classical site is at the Achilles tendon. Here, the ligaments and tendons interdigitate into cancellous bones through fibrocartilage connections. The enthesis at the Achilles tendon suffers repeated damage and repair even in normal subjects, but, in AS, the process becomes clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to enthesitis, peripheral synovitis is also present in some patients with AS. The synovitis is characterized by hypervascularity and infiltration by macrophages, T cells, and B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic influences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors are of overwhelming importance in susceptibility to AS. First, second, and third degree relatives of patients with AS have markedly increased risks of developing AS (relative risks of 94, 25, and 4, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/11\">",
"     11",
"    </a>",
"    ]. The mode of inheritance is oligogenic with multiplicative interaction among loci. The number of loci involved was initially estimated to range from three to nine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The association with the HLA-B27 gene was recognized in 1973 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] and is by far the strongest. The overall contribution to AS heritability by HLA-B27 is estimated at approximately 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several large genome-wide association studies (GWAS) done in several populations of European [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/17-19\">",
"     17-19",
"    </a>",
"    ] and Han Chinese descent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/20\">",
"     20",
"    </a>",
"    ] have identified a total of at least 15 other loci, which, unlike HLA-B27, are not part of the major histocompatibility complex (MHC) but which, like HLA-B27, are associated with an increased risk of AS (",
"    <a class=\"graphic graphic_table graphicRef85593 \" href=\"UTD.htm?0/42/685\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/16\">",
"     16",
"    </a>",
"    ]. Two additional associated genes have been identified in a large Chinese cohort. These include one at a locus between EDIL3 and HAPLN1 at 5q14.3 and another within ANO6 at 12q12 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the total contribution of all these non-MHC genes to AS heritability is many times less than that of HLA-B27. The two non-MHC genes with the highest contributions and of great interest in AS are ERAP1 (endoplasmic reticulum aminopeptidase 1, previously known as &ldquo;aminopeptidase regulating tumor necrosis factor receptor shedding 1&rdquo; or ARTS-1) and interleukin (IL)-23 receptor (IL-23R). The biological activities of some of these genes and their products are discussed below.",
"   </p>",
"   <p>",
"    Several other candidate genes and regions have been proposed in the past but have not been confirmed by GWAS. These include the cytochrome CYP2D6 genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/21\">",
"     21",
"    </a>",
"    ], certain ANKH variants [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/22\">",
"     22",
"    </a>",
"    ], the IL-1 gene cluster [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], and tumor necrosis factor (TNF)-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tumor necrosis factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;GWAS studies have also demonstrated an association between AS and a region of the chromosome encompassing the genes LTBR (lymphotoxin beta receptor) and TNFRSF1A (tumor necrosis factor receptor 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/16\">",
"     16",
"    </a>",
"    ]. Multiple randomized trials have shown that biologic agents that specifically inhibit TNF-alpha suppress the symptoms of AS, as well as the acute phase response. Hence, there is no doubt that TNF-alpha is a critical mediator of inflammation in AS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/27\">",
"     27",
"    </a>",
"    ]. However, these TNF-alpha inhibitors do not arrest the progression of bone erosions or syndesmophyte formation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Osteoimmunology: Bone erosion and new bone formation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DISEASE ASSOCIATION WITH HLA-B27",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLA-B27 is present in about 90 to 95 percent of AS patients in the United States, Europe, and China. The approximate prevalence of HLA-B27 among the population in the United States is 6 percent, in Europe is 4 to 14 percent with a higher percentage being found in the north, and in China is 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The association of AS and HLA-B27 also exists in most other ethnic groups worldwide, so that, with minor exceptions, the prevalence of AS parallels that of HLA-B27 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. As examples, a high incidence of both AS and HLA-B27 is found among the native peoples of North America (eg, 50 percent incidence in the Haida) and of the circumpolar arctic and subarctic regions of Eurasia.",
"   </p>",
"   <p>",
"    By comparison, both HLA-B27 and AS are virtually absent in several populations, including the (unmixed) native populations of South America, the Bantus and Bushmen of equatorial and South Africa, and the aboriginals of Australia. The association of HLA-B27 and disease also extends to other forms of SpA, though to a lesser degree [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall contribution to AS heritability of HLA-B27 is estimated at 23.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/16\">",
"     16",
"    </a>",
"    ]. However, within a population, only 5 percent of HLA-B27 positive individuals develop SpA. Nevertheless, HLA-B27 remains the strongest research clue to the pathogenesis of AS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Structure of HLA-B27",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLA-B27 is an HLA-B allele of the MHC class I molecules. Even before the quaternary structure of HLA-B27 and other HLA class I alleles had been resolved, it was known that a major function of HLA class I molecules is to present antigenic peptides to the T cell receptors (TCR) of CD8+ T lymphocytes. Some information relating to HLA class I structure and function is important to understanding the possible roles of HLA-B27 in spondyloarthritis and is summarized below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The HLA class I molecule is composed of a polymorphic heavy chain, 45 kDa in molecular weight, non-covalently complexed with a 12 kDa monomorphic unit, beta-2-microglobulin. Polymorphism in the heavy chain accounts for the various alleles of the HLA-A, -B, and -C loci.",
"     </li>",
"     <li>",
"      The heavy chain itself is composed of three domains. The first two domains (alpha-1 and alpha-2) together form two antiparallel helices resting on a platform of an eight-stranded pleated sheet, which itself rests on two barrel-shaped structures derived from the third domain (alpha-3) and beta-2-microglobulin (",
"      <a class=\"graphic graphic_figure graphicRef71117 \" href=\"UTD.htm?40/39/41586\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Resting inside the platform is an antigenic peptide that is usually 8 to 11 amino acids in length. The residues of each peptide are numbered from the amino terminus to the carboxyl terminus (eg, P1 for the first peptide residue). These peptides are derived from endogenous proteins and from proteins of viruses and bacteria that have invaded the cells. The antigenic peptide is in contact with the heavy chain at several locations known as &ldquo;pockets.&rdquo; These pockets are designated from A to F throughout the length of the platform from the amino to the carboxyl termini (",
"      <a class=\"graphic graphic_figure graphicRef68628 \" href=\"UTD.htm?20/3/20534\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The feature that distinguishes HLA-B27 from most other HLA class I alleles is in the residues of the so-called &ldquo;B pocket&rdquo; of the heavy chain. This B pocket accommodates the second residue of the antigenic peptide (P2). The glutamic acid residue lining this HLA-B27 B pocket is particularly important, dictating that the B pocket of HLA-B27 can accommodate only an arginine residue from the peptide. As a result, the most suitable peptide residue is arginine. Indeed, sequencing of HLA-B27 endogenous peptides show that most antigenic peptides associated with HLA-B27 have arginine as the second residue [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/35-37\">",
"       35-37",
"      </a>",
"      ]. There can be exceptions to this motif. HLA-B27 has been reported to accommodate very long peptides and also peptides not having arginine as the second residue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516012992\">",
"    <span class=\"h2\">",
"     HLA-B27 subtypes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Subtype and disease association",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 49 subtypes of HLA-B27 have been characterized. Some of the alleles are silent mutations generating the same proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/15,38\">",
"     15,38",
"    </a>",
"    ]. Of 24 protein subtypes, at least 13 subtypes share an identical B pocket that favors binding of an arginine at P2 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major direction of research has been to assess the degree of association of each subtype with SpA. The following is a summary of the salient points [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      B*2705 is the ancestral subtype and is by far the most frequent subtype found in Caucasians; it is highly associated with AS. B*2705 is further subdivided into B*27052, B*27053, B*27054, B*27056, and B*27056 by silent substitutions.",
"     </li>",
"     <li>",
"      B*2704 is also a major subtype in frequency. It is the predominant subtype in Chinese and Japanese. This serotype is also associated with SpA.",
"     </li>",
"     <li>",
"      B*2702, a major subtype in Mediterranean populations, is associated with AS.",
"     </li>",
"     <li>",
"      The subtypes which have been reported to be, at most, weakly associated with SpA are B*2706 and B*2709. B*2706 is found in normal individuals in Thailand, Singapore, Taiwan, and Indonesia. B*2709, which is present in 25 percent of the healthy population of Sardinia and which has generally not been found in those with spondyloarthritis in Sardinia [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/11,41,42\">",
"       11,41,42",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Since B*2706 and B*2709 are not associated with AS, differences in their structures from those of AS-associated alleles (eg, B*2704 and B*2705) might provide clues to the critical features of the HLA-B27 molecule that are responsible for the risk of AS. The arthritis-sparing B*2709 differs from the arthritis-causing B*2705 in only one residue at 116 [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/41\">",
"       41",
"      </a>",
"      ]. This is aspartic acid in B*2705 but is histidine in the arthritis-sparing B*2709 [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/43\">",
"       43",
"      </a>",
"      ]. The reason why these subtypes are AS-sparing remains uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Subtype and peptide specific binding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information derived from the crystal structure of the HLA-B27 first reported in 1991 was limited by the fact that those structures were derived from complexes with a variety of peptides. Crystal structures of HLA-B27 complexed separately with at least seven separate peptides have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Crystal structures of HLA-B*2705 complexed separately with three individual viral peptides confirm that the B pocket of HLA-B27 is of major importance and binds predominantly to a peptide with arginine as the second peptide residue. The F pocket of B*2705, which anchors the C-termini of the peptides, can accommodate aliphatic, aromatic, and basic residues. While these two anchoring peptide residues are buried, the peptide residues P1, P4, and P6 to P8 are exposed and, therefore, are likely responsible for contact with T cell receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As noted above, the difference between arthritis-sparing B*2709 and the arthritis-causing B*2705 is at residue 116 which is aspartic acid in B*2705 but is occupied by tyrosine and histidine in the arthritis-sparing subtypes B*2706 and B*2709, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/43\">",
"       43",
"      </a>",
"      ]. Study of crystal structures with single peptides show that residue 116 forms part of the F pocket and is responsible for determining the C-terminus anchoring motif of the arthritis-causing peptides.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Subtype and peptide conformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The difference in disease association of HLA-B27 subtypes may result from an ability to bind the same peptide in different conformations. As an example, the arthritis&ndash;causing B*2705 and arthritis-sparing B*2709 derived proteins differ in the ways they can bind a particular self-peptide (VIPR, sequence RRKWRRWHL) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/47\">",
"     47",
"    </a>",
"    ]. While a single conformation of this peptide with B*2709 is observed (referred to as the canonical or p4-alpha conformation), binding to B*2705 can be in a similar (canonical) orientation or in one in which the fifth residue of the peptide, which is an arginine, associates with the aspartic acid at position 116 of B*2705. This conformation, termed p6-alpha, drastically alters the conformation of the rest of the peptide. This linkage with residue 116 does not occur with the arthritis-sparing B*2709 histidine at the same position. In other words, this peptide has only one conformation with the arthritis-sparing B*2709 but has two different conformations with the arthritis-causing B*2705. That this unusual conformation is biologically relevant is suggested by the finding that one T lymphocyte clone can recognize the peptide only when it is bound to B*2705 but not to B*2709.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     CD8+ T cells and molecular mimicry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molecular mimicry theory proposes that certain microbial peptides are very similar to self-peptides, and infection with such microbes will lead to autoimmunity. The classical function of the HLA-B class I proteins is to present peptides to activate CD8+ T lymphocytes (",
"    <a class=\"graphic graphic_figure graphicRef55882 \" href=\"UTD.htm?24/53/25427\">",
"     figure 3",
"    </a>",
"    ). The CD8+ T lymphocytes involvement in the pathogenesis of AS is supported by the association of disease with polymorphisms in the RUNX3 gene. This gene is critically involved in differentiation of CD8+ T lymphocytes. What is the role of CD8+ T lymphocytes in AS? Normally, the host CD8+ T lymphocytes are tolerant to HLA-B27 presenting self-peptides, but they can develop adaptive immunity to microbial peptides. A very large number of publications have appeared in search of microbial peptides that mimic self-peptides and thus result in autoimmunity; other studies have sought to identify HLA-B27-specific CD8+ T lymphocytes (cytotoxic T lymphocytes or CTL) that are specific for self-peptides [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least two self-peptides have been identified that can activate CD8+ T lymphocytes in AS patients. One is a peptide derived from type VI collagen. It was able to stimulate T lymphocytes obtained from four out of seven synovial fluid samples [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/50\">",
"     50",
"    </a>",
"    ]. Another is derived from human vasoactive intestinal peptide receptor 1 (VIP1R). The VIP1R peptide is homologous to a peptide derived from the Epstein&ndash;Barr virus protein (LMP2). Peptides derived from these proteins share five of nine amino acid residues (RRKWRRWHL and RRRWRRLTV, for residues 400 to 408 of VIP1R and for residues 236 to 244 of EBV-LMP2, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/51\">",
"     51",
"    </a>",
"    ]. When lymphocytes from subjects with the arthritis-prone B*2705 allele were compared with B*2709 subjects, a higher reactivity to VIP1R was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/51\">",
"     51",
"    </a>",
"    ]. The VIP1R and the LMP2 are also the only pair of self- and pathogen-derived HLA-B27 peptides that have been compared by x-ray crystallography [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/52\">",
"     52",
"    </a>",
"    ]. Alternative binding conformations of peptides to B*2705 (referred to as p4-alpha and p6-alpha) occur while, with B*2709, only one conformation occurs: the p4-alpha",
"   </p>",
"   <p>",
"    The discovery that ERAP1 (ARTS-1) is a gene for AS suggests that the pathway above might indeed be an important pathway in AS, because one of the biological activities of ERAP1 is to trim peptides to load them into MHC class I molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/53\">",
"     53",
"    </a>",
"    ]. Further evidence of a role for ERAP1 are the gene-gene interaction that exists between ERAP1 and HLA-B27 and the lack of an association of ERAP1 with HLA-B27-negative AS. There are two protective alleles in ERAP1; recombinant protein studies show that their rate of peptide trimming is remarkably slower than the wild type ERAP1 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     HLA-B27 heavy chain homodimer formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second model of why HLA-B27 is associated with AS is based upon the observation that HLA-B27 heavy chains can form stable dimers with no beta-2-microglobulin. It has been postulated that such dimers can engage receptors on several types of cells in a way different from the classical structure [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. A hypothetical model of the homodimers has been reported (",
"    <a class=\"graphic graphic_figure graphicRef79650 \" href=\"UTD.htm?1/43/1718\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These homodimers of HLA-B27 are ligands for natural killer (NK) receptors (NKRs). The particular NKRs involved are the killer Ig-like receptors (KIRs). NKRs are divided into two groups with suffixes 2D and 3D depending on whether they have two or three immunoglobulin-like domains. Even before the discovery of the HLA-B27 homodimers, it has been known that the 3-domain KIRs (KIR3DL1 and KIR3DL2) bind to HLA-B27. The HLA-B27 homodimers are ligands for a number of NKRs including KIR3DL1, KIR3DL2, LILRB2, and LILRA1. KIR3DL2 is the most interesting because, unlike the others, it binds only to the HLA-B27 homodimers and does not bind to heterodimers.",
"   </p>",
"   <p>",
"    KIR3DL2 are expressed on NK as well as T cells and transmit inhibitory signals. Among other activities, these receptors mediated T cell resistance to apoptosis. Spondyloarthritis patients, when compared with healthy controls, have a significant increase in the number of KIR3DL2 positive NK and CD4 T cells. The hypothesis is that expression of the HLA-B27 homodimers in spondyloarthritis patients leads to expansion of these KIR3DL2 NK and T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If this hypothesis is correct, a potential target of AS therapy would be the interaction between these dimers and the corresponding receptors. An antibody which might fulfill this potential has been generated and is under study [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     HLA-B27 protein misfolding and autoinflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third hypothesis of why HLA-B27 is associated with AS is based upon the biogenesis of the HLA-B27 molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The proposed mechanism involves the activation of an inflammatory response due to HLA-B27 generation of an endoplasmic reticulum unfolded protein response (ERUPR), as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HLA molecules mature inside a compartment of the cell designated as the endoplasmic reticulum (ER). Inside the ER, HLA molecules are first generated as free heavy chains that interact with chaperone proteins before becoming non-covalently associated with beta-2-microglobulin light chains and being subsequently loaded with an antigenic peptide. Only after all components have been assembled is an HLA molecule considered to be fully matured to be exported to the cell surface (",
"      <a class=\"graphic graphic_figure graphicRef55882 \" href=\"UTD.htm?24/53/25427\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      During different phases of maturation processes, proteins adopt different conformational structures. The evolution in conformation is described as &ldquo;folding.&rdquo; Thus, the structure of HLA-B27 reported in 1992 was that of a fully folded mature HLA-B27 molecule [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/36\">",
"       36",
"      </a>",
"      ]. Molecules before reaching this stage are described as being &ldquo;unfolded.&rdquo; Unfolded molecules are usually retained in the ER. In general, when unfolded proteins excessively accumulate in the ER, they induce a signal described as the ER unfolded protein response (ERUPR). In macrophages derived from HLA-B27 transgenic rats, this process can lead to the release of interleukin (IL)-23, which might, in turn, activate the proinflammatory IL-17-positive T lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no convincing evidence that ER unfolded protein response is responsible for the activation of the IL-17 axis in AS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the HLA-B27 folding hypothesis is as follows (",
"    <a class=\"graphic graphic_figure graphicRef68574 \" href=\"UTD.htm?9/57/10135\">",
"     figure 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unfolded proteins accumulate in the ER.",
"     </li>",
"     <li>",
"      An overloading protein response ensues.",
"     </li>",
"     <li>",
"      The overloading protein response then leads to release of IL-23 and to activation of the proinflammatory IL-17 T lymphocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25857154\">",
"    <span class=\"h2\">",
"     Role of ERAP1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The discovery that the ERAP1 gene (endoplasmic reticulum aminopeptidase 1, previously known as &ldquo;aminopeptidase regulating tumor necrosis factor receptor shedding 1&rdquo; or ARTS-1), especially the loss-of-function variants, is associated with AS provides a very important clue for research on the pathogenesis of AS.",
"   </p>",
"   <p>",
"    In AS, the biological activities of ERAP1 are closely associated with those of HLA-B27. This association is demonstrated by two findings. The first is that the ERAP1 variants which are found in AS patients are present mostly in patients who are HLA-B27 positive rather than HLA-B27 negative [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/19\">",
"     19",
"    </a>",
"    ]. The second finding is that ERAP1 dysfunction appears to spare those HLA-B27 subtypes which do not cause AS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ERAP1 is an aminopeptidase. It trims peptides inside the endoplasmic reticulum to the correct lengths so that they can be loaded into HLA class I molecules. Thus, an ERAP1 dysfunction may lead to a change of peptide repertoires presented by HLA-B27 or may promote homodimer formation or misfolding [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Structure of HLA-B27'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25857161\">",
"    <span class=\"h2\">",
"     Macrophages and AS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The homodimer and the misfolding hypotheses suggest that AS is not a classical antigen-specific autoimmune disease but perhaps an &ldquo;autoinflammatory disease&rdquo; related to innate immunity. Inflammation is policed by two different types of macrophages: the proinflammatory M1 and the immunoregulatory M2 macrophages. In spondyloarthritis, there is a predominance in M2 macrophages. The cause of this and the way by which this can promote spondyloarthritis remain to be investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the elegance of these hypotheses, it is not known whether any of the theories accurately reflects the disease process. Some information has been provided by studies using animal models, but testing of these hypotheses in humans will be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     HLA-B27 transgenic animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1990, it was found that the introduction of the HLA-B27 gene into rats, together with the human beta-2-microglobulin gene, resulted in a syndrome with features similar to those of human reactive arthritis, including inflammation of the peripheral and vertebral joints, male genital tract, gastrointestinal tract, skin, nails, and heart [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/66\">",
"     66",
"    </a>",
"    ]. In addition, the degree of susceptibility to inflammatory disease in an individual syngeneic rat line correlated with the level of HLA-B27 gene expression in that line [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/67\">",
"     67",
"    </a>",
"    ]. When extra human beta-2-microglobulin was bred into male rats in this line, there was a higher prevalence of arthritis, but colitis was absent. The arthritis also showed characteristics of spondyloarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/68\">",
"     68",
"    </a>",
"    ]. This model supported the important concept that it is the HLA-B27 gene, and not a closely linked gene, that predisposes to arthritis. Other animal models are available to study other aspects of AS, such as the osteo-immunological aspects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CYTOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequently dramatic response of AS patients to TNF-alpha blockers indicates that TNF-alpha plays a major role in the pathogenesis of the spondyloarthropathies; however, that response is sometimes incomplete [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/27\">",
"     27",
"    </a>",
"    ]. Such clinical observations and other lines of evidence suggest that other cytokines also play a role in AS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/70\">",
"     70",
"    </a>",
"    ]. Three of the AS genes identified by genome-wide association studies are related to cytokines: ERAP1, IL-23R, and IL-1R2 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, the",
"    <span class=\"nowrap\">",
"     IL-23/IL-17",
"    </span>",
"    axis appears to be involved in AS pathogenesis. IL-23R is expressed on IL-17+ T lymphocytes. The identification of IL-23R and IL-12B gene polymorphisms in AS suggests that the proinflammatory IL-17 plays a role in arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/70\">",
"     70",
"    </a>",
"    ]. Possible involvement of the",
"    <span class=\"nowrap\">",
"     IL-23/IL-17",
"    </span>",
"    axis in AS is suggested by experiments showing that macrophages induced from peripheral blood monocytes of AS patients, compared with monocytes of controls, release more IL-23 in response to activation by a TLR4 agonist [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/62\">",
"     62",
"    </a>",
"    ]. Additionally, IL-17+ cells, mostly non-T cells, were found in a higher percentage in the subchondral bone marrow of AS patients compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/71\">",
"     71",
"    </a>",
"    ]. Lastly, IL-17+ mast cells have been detected in the synovial compartment of patients with spondyloarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/72\">",
"     72",
"    </a>",
"    ]. Clinical trials testing anti-IL17 antibody as a therapeutic agent will further test the role of the",
"    <span class=\"nowrap\">",
"     IL-17/IL-23",
"    </span>",
"    axis in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/73\">",
"     73",
"    </a>",
"    ]. A role for IL-23 in entheseal inflammation and bone remodeling has been suggested by studies in mouse models of SpA. (See",
"    <a class=\"local\" href=\"#H427628909\">",
"     'Entheseal IL-23 responsive T cells'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Infections and AS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible infectious contribution to AS has been pursued, but the data accumulated do not unequivocally establish any particular infection as a trigger or cause of AS. As an example, a role for Klebsiella pneumoniae infection has been investigated. The mean level of serum anti-Klebsiella antibodies is higher in patients with AS compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/74\">",
"     74",
"    </a>",
"    ]. An abnormal T lymphocyte response to Klebsiella infection has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/75\">",
"     75",
"    </a>",
"    ]. Considerable overlap exists between the response observed among patients and control individuals.",
"   </p>",
"   <p>",
"    However, there is no convincing evidence to demonstrate that Klebsiella pneumoniae or any other infectious agent is a critical causative factor in AS. Klebsiella pneumoniae bacteria are commensal in the bowel of many normal subjects. There are no well-controlled studies aimed at eradicating Klebsiella in the bowel to control AS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Infections in reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to AS, bacteria clearly play a pivotal role in the development of reactive arthritis (ReA). In the post-enteric form, Shigella, Salmonella, Yersinia, and Campylobacter species are arthritogenic. In the post-venereal form, Chlamydia trachomatis is the causative pathogen. The pathogenesis of Chlamydia-induced reactive arthritis is described in more detail below. Intravesical installation of Bacillus Calmette-Guerin (BCG) for the treatment of bladder cancer may rarely cause ReA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/76\">",
"     76",
"    </a>",
"    ]. In the arthropathy of atypical cat-scratch disease, Bartonella henselae has been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/77\">",
"     77",
"    </a>",
"    ]. These bacteria infect the mucosal surfaces of the bowel and the urogenital tracts.",
"   </p>",
"   <p>",
"    One possible explanation for the association is a reaction to bacteria in the synovium of affected joints. Studies utilizing electron microscopy or antibacterial antibodies have documented the presence of fragments of mucosal bacteria in the joints [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. The question which follows this demonstration is: Are the bacteria detected in the joints viable or not?",
"   </p>",
"   <p>",
"    If the bacteria found in synovial tissue are viable, the arthritis can be considered as being &ldquo;infective&rdquo; instead of &ldquo;reactive.&rdquo; Thus far, attempts to culture viable bacteria from joints of reactive arthritis patients have almost always been unsuccessful. That is the reason why the arthritis is designated as reactive and not infective.",
"   </p>",
"   <p>",
"    Polymerase chain reaction (PCR) technology has been utilized to detect bacterial nucleotide sequences in the tissues or the synovial fluids of patients with various types of arthritis. The results of some illustrative studies in the spondyloarthritis patients and those with other diseases and in healthy controls can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCR to detect 16S rRNA, a highly conserved sequence found in all bacteria, has also been utilized to assess for the presence of bacterial genetic material in the joints of patients with reactive arthritis. In one study, for example, synovial fluids were examined in 65 patients, of which 26 samples displayed evidence of bacterial DNA [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/80\">",
"       80",
"      </a>",
"      ]. However, the presence of bacterial nucleotides is not specific for any form of arthritis. Bacterial 16S rRNA is observed in patients with rheumatoid and other arthritides.",
"     </li>",
"     <li>",
"      Many of the bacterial species detected are not commonly regarded as being arthritis-causing. In many joints, multiple species can be detected in the same joint sample.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies indicate that the presence of bacterial DNA in synovial fluid or tissue is common to many bacteria, is common to many types of arthritis, and occurs even in normal individuals. The role of bacterial DNA in synovium remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11541214\">",
"    <span class=\"h3\">",
"     Chlamydia-induced reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two species of Chlamydia can induce reactive arthritis: C. trachomatis and C. pneumoniae. C. pneumoniae infections are extremely common. The incidence of C. pneumoniae-induced arthritis is unknown but is probably less than arthritis triggered by C. trachomatis. C. trachomatis infections are also very common. Because most of the C. trachomatis infections are silent and because the subsequent arthritis is usually transient, the incidence of C. trachomatis-induced reactive arthritis is also difficult to assess. It may be as common as rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with Chlamydia-induced arthritis and in some patients with undifferentiated arthritis, the Chlamydia persists in the joints with a modulated pattern of gene expression. In the past, it had been assumed that all of the C. trachomatis detected in the joints were of the genital serovars. Unexpectedly, however, one study has subsequently shown that all of the 36 positive synovial samples identified in that study were ocular serovars and not genital serovars. Whether these ocular serovars induce arthritis via infections of the genital tract remains to be studied [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/82\">",
"     82",
"    </a>",
"    ]. How the Chlamydia escapes immune surveillance is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These questions concerning the biology of Chlamydia in reactive arthritis are important, because preliminary studies indicate that treatment with a combination of antibiotics might be effective for patients presenting with undifferentiated spondyloarthritis in whom Chlamydial DNA could be detected by PCR either in peripheral blood or in synovial fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Interaction between infection and HLA-B27",
"    </span>",
"    &nbsp;&mdash;&nbsp;While HLA-B27 does not appear to have a unique role in allowing bacterial antigens or DNA access to joints, the presence of HLA-B27 may affect the host response to bacterial components. The bacteria that are most often associated with reactive arthritis have two features in common: they are invasive and also are facultatively intracellular microbes. The effect of HLA-B27 on each of these two characteristics has been evaluated in vitro. Two reports are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mouse fibroblast cell line transfected with HLA-B7 was more resistant to invasion by arthritis-causing bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In some human cell lines transfected with HLA-B27, invading bacteria are able to survive at a higher rate during several days in culture [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/86\">",
"       86",
"      </a>",
"      ], a phenomenon that is dependent upon the amino acid sequence determining the antigen binding pocket of the HLA-B27 molecule [",
"      <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies suggest that HLA-B27 can modify cellular activities that could be important in pathogenesis. However, these experiments concerning the effect of HLA-B27 on bacterial invasion and survival have been difficult to reproduce in different laboratories, and there is a gap between laboratory observations and possible translation into clinical medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14182679\">",
"    <span class=\"h3\">",
"     Infection and innate immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The innate immune response to bacteria may also have a role in determining whether reactive arthritis develops following exposure to an infectious agent. Toll-like receptors (TLR) are a family of immune cell surface receptors that influence the innate immune response to microbes following recognition of pathogen-associated molecular patterns on these organisms. TLR2 and TLR4 are two TLR that are especially important in the response to bacteria that induce reactive arthritis. In a cohort of patients studied following a Salmonella outbreak, individuals with variants of TLR2, but not those with TLR4, were at increased risk for the development of reactive arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=see_link&amp;anchor=H9421044#H9421044\">",
"     \"An overview of the innate immune system\", section on 'Toll-like receptors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1221077\">",
"    <span class=\"h1\">",
"     ROLE OF THE GASTROINTESTINAL TRACT IN SpA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relationship of inflammatory disease in the gastrointestinal tract to SpA is supported by several clinical observations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/90\">",
"     90",
"    </a>",
"    ]. These include findings on ileocolonoscopy and biopsy of subclinical gut inflammation in about two-thirds of patients with SpA; the eventual development of symptomatic inflammatory bowel disease (IBD) in approximately 6.5 percent of SpA patients presenting without symptoms of IBD; the presence of AS in 4 to 10 percent of patients with ulcerative colitis and Crohn&rsquo;s disease (CD); and findings of sacroiliitis on plain radiographs in a significant proportion of patients with CD, many of whom do not have inflammatory back pain.",
"   </p>",
"   <p>",
"    There are several pathogenetic possibilities which may account for the overlap between SpA and bowel inflammation, particularly the association of both conditions with many of the same genes, including variants at 1q32, STAT3, IL-12B, and IL-23R [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/91\">",
"     91",
"    </a>",
"    ]. The sharing of these genes and other evidence suggest that the",
"    <span class=\"nowrap\">",
"     IL-23/IL-17",
"    </span>",
"    axis might play a proinflammatory role in both diseases, mediated via both innate and acquired immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. A detailed discussion of potential mechanisms for the induction of rheumatic symptoms by gastrointestinal disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6377?source=see_link\">",
"     \"Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OSTEOIMMUNOLOGY: BONE EROSION AND NEW BONE FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most characteristic feature of AS is new bone formation leading to ankylosis of the SI joints and syndesmophytes in the spine. Since the symptoms of inflammation and the acute phase response respond dramatically to treatment by TNF-alpha blockers, it was expected that the radiographic progression in these patients would also be arrested by TNF blockade, as it is in rheumatoid arthritis (RA). However, this has not been the case in short-term studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/94-96\">",
"     94-96",
"    </a>",
"    ]. The bone remodeling processes in SpA, both in humans and in animal models, appear to be &ldquo;uncoupled&rdquo; from the inflammatory processes, unlike the close relationship of inflammatory disease and bone injury in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/28,97\">",
"     28,97",
"    </a>",
"    ]. Nevertheless, whether inflammation necessarily precedes new bone formation remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insights into the differences between SpA and RA have come from a comparison of the gene expression profiles of synovial tissues obtained from patients with each of these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/99\">",
"     99",
"    </a>",
"    ]. SpA synovial tissues, compared with those from patients with RA, exhibited substantial upregulation of genes related to muscle and myofibroblast biology, termed myogenes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/100\">",
"     100",
"    </a>",
"    ]. The cells found in the intimal lining layer and in the synovial sublining that express these genes appear to be myofibroblasts, a form of activated fibroblasts, which also express contractile proteins. The gene expression signature seen in this study suggested that the major bone-forming signaling pathways important in SpA involve platelet-derived growth factor, transforming growth factor-beta, and Wnt signaling.",
"   </p>",
"   <p>",
"    In physiological development, there are two bone forming processes: the membranous and the endochondral. In enthesitis, the endochondral process seems to predominate, based upon evidence from animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/101\">",
"     101",
"    </a>",
"    ]. There are two major pathways in the endochondral processes: one involving the bone morphogenic proteins (BMP) and the other involving the &ldquo;wingless&rdquo; (Wnt) family of proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. Wnt signalling can be modulated by prostaglandin E2, accounting for the clinical observation that continuous use of NSAIDs can suppress new bone formation in AS [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. These bone-forming pathways are also regulated by suppressors such as noggin, sclerostin, and Dickkopf-1 (DKK-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/106\">",
"     106",
"    </a>",
"    ]. These two pathways are an active focus of investigation. Studies using an animal model suggest that DKK-1 and the Wnt pathway play a crucial role in bone fusion in sacroiliitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/107\">",
"     107",
"    </a>",
"    ]. Genome-wide association studies suggest possible participation of two genes, EDIL3 and HALPN1 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H427628909\">",
"    <span class=\"h1\">",
"     ENTHESEAL IL-23 RESPONSIVE T CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in mice have suggested that IL-23 overexpression alone may result in enthesitis and in joint disease that resembles AS in humans in important respects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/108\">",
"     108",
"    </a>",
"    ]. These studies, which focus on the role of entheseal T cells, have helped to generate hypotheses that may provide a unified explanation for the predilection for disease to occur at entheses, as well as findings in these sites of inflammation and new bone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. The study found entheseal-resident T cells that were CD3+CD4���CD8&ndash;IL-23R+ and RAR-related orphan receptor gamma t (ROR-&gamma;t) positive. These cells responded vigorously (and independently of Th17 cells) to IL-23 by releasing IL-17 and IL-22. IL-17 induced local inflammatory change, and IL-22 induced osteoblast-mediated bone remodeling. These T cells were also present in the aortic root and valve but were not present in the myocardium, consistent with the aortitis that may be seen in patients with AS.",
"   </p>",
"   <p>",
"    Further studies will be required to determine whether similar cells and mechanisms may underlie human SpA and what processes may trigger IL-23 production and this cascade of events in AS. However, these animal studies provide additional support to hypotheses suggesting links between increased levels of IL-23 in SpA patients; the possible induction of IL-23 by the endoplasmic reticulum unfolded protein response to HLA-B27; the potential capacity of gut bacterial flora to trigger IL-23 production; and the preference in AS for a particular isoform of IL-23R (",
"    <a class=\"graphic graphic_figure graphicRef87848 \" href=\"UTD.htm?13/12/13505\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/51/12090/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"       \"Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 90 percent of the risk of developing ankylosing spondylitis (AS) is heritable. The most powerful of the genetic risk factors is related to the HLA-B27 molecule. Given the important role that HLA-B27 plays in risk, several possible mechanisms have been proposed. However, despite intense interest and active investigation, there is no general agreement on how HLA-B27 contributes to disease susceptibility. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Key observations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Disease association with HLA-B27'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple additional genes associated with AS have been discovered in addition to HLA-B27 but contribute to risk to a lesser degree. The ERAP1 gene may have an important role. Several of the associated genes are related to cytokines. In addition to TNF-alpha, IL-17 may also be an important cytokine in AS. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Disease association with HLA-B27'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25857154\">",
"       'Role of ERAP1'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Cytokines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hallmarks of spondyloarthritis are bone erosion, syndesmophyte formation, and, in some patients, fusion of the spine and sacroiliac joints. These processes can progress despite treatment with TNF-alpha blockers. Understanding and controlling these processes will be critical for prevention of deformities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Key observations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Osteoimmunology: Bone erosion and new bone formation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/1\">",
"      Baeten D, Breban M, Lories R, et al. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum 2013; 65:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/2\">",
"      Tam LS, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010; 6:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/3\">",
"      Cawley MI, Chalmers TM, Kellgren JH, Ball J. Destructive lesions of vertebral bodies in ankylosing spondylitis. Ann Rheum Dis 1972; 31:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/4\">",
"      Neidhart M, Baraliakos X, Seemayer C, et al. Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis. Ann Rheum Dis 2009; 68:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/5\">",
"      Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006; 54:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/6\">",
"      Appel H, Kuhne M, Spiekermann S, et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006; 54:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/7\">",
"      Fran&ccedil;ois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006; 65:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/8\">",
"      Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat 2001; 199:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/9\">",
"      Benjamin M, McGonagle D. The enthesis organ concept and its relevance to the spondyloarthropathies. Adv Exp Med Biol 2009; 649:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/10\">",
"      Baeten D, De Keyser F. The histopathology of spondyloarthropathy. Curr Mol Med 2004; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/11\">",
"      Taurog JD. The mystery of HLA-B27: if it isn't one thing, it's another. Arthritis Rheum 2007; 56:2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/12\">",
"      Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997; 40:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/13\">",
"      Brown MA, Laval SH, Brophy S, Calin A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis 2000; 59:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/14\">",
"      Brewerton DA, Hart FD, Nicholls A, et al. Ankylosing spondylitis and HL-A 27. Lancet 1973; 1:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/15\">",
"      Schlosstein L, Terasaki PI, Bluestone R, Pearson CM. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med 1973; 288:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/16\">",
"      Reveille JD. Genetics of spondyloarthritis--beyond the MHC. Nat Rev Rheumatol 2012; 8:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/17\">",
"      Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010; 42:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/18\">",
"      Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/19\">",
"      Evans DM, Spencer CC, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011; 43:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/20\">",
"      Lin Z, Bei JX, Shen M, et al. A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet 2012; 44:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/21\">",
"      Brown MA, Edwards S, Hoyle E, et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Hum Mol Genet 2000; 9:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/22\">",
"      Tsui HW, Inman RD, Paterson AD, et al. ANKH variants associated with ankylosing spondylitis: gender differences. Arthritis Res Ther 2005; 7:R513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/23\">",
"      Timms AE, Crane AM, Sims AM, et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 2004; 75:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/24\">",
"      Chou CT, Timms AE, Wei JC, et al. Replication of association of IL1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Ann Rheum Dis 2006; 65:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/25\">",
"      Wu Z, Gu JR. [A meta-analysis on interleukin-1 gene cluster polymorphism and genetic susceptibility for ankylosing spondylitis]. Zhonghua Yi Xue Za Zhi 2007; 87:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/26\">",
"      Zhu X, Wang Y, Sun L, et al. A novel gene variation of TNFalpha associated with ankylosing spondylitis: a reconfirmed study. Ann Rheum Dis 2007; 66:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/27\">",
"      McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/28\">",
"      Schett G, Landew&eacute; R, van der Heijde D. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis 2007; 66:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/29\">",
"      Feltkamp TE, Mardjuadi A, Huang F, Chou CT. Spondyloarthropathies in eastern Asia. Curr Opin Rheumatol 2001; 13:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/30\">",
"      Reveille JD, Hirsch R, Dillon CF, et al. The prevalence of HLA-B27 in the US: data from the US National Health and Nutrition Examination Survey, 2009. Arthritis Rheum 2012; 64:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/31\">",
"      Khan MA. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995; 7:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/32\">",
"      Gonzalez-Roces S, Alvarez MV, Gonzalez S, et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997; 49:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/33\">",
"      Lau CS, Burgos-Vargas R, Louthrenoo W, et al. Features of spondyloarthritis around the world. Rheum Dis Clin North Am 1998; 24:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/34\">",
"      Thjodleifsson B, Geirsson AJ, Bj&ouml;rnsson S, Bjarnason I. A common genetic background for inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis Rheum 2007; 56:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/35\">",
"      Madden DR, Gorga JC, Strominger JL, Wiley DC. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991; 353:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/36\">",
"      Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1 A resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992; 70:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/37\">",
"      Yamaguchi A, Tsuchiya N, Mitsui H, et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients. Evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum 1995; 38:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/38\">",
"      Reveille JD. Recent studies on the genetic basis of ankylosing spondylitis. Curr Rheumatol Rep 2009; 11:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/39\">",
"      Kim TH, Uhm WS, Inman RD. Pathogenesis of ankylosing spondylitis and reactive arthritis. Curr Opin Rheumatol 2005; 17:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/40\">",
"      Khan MA. Update: the twenty subtypes of HLA-B27. Curr Opin Rheumatol 2000; 12:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/41\">",
"      D'Amato M, Fiorillo MT, Carcassi C, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995; 25:3199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/42\">",
"      Koh WH, Boey ML. Ankylosing spondylitis in Singapore: a study of 150 patients and a local update. Ann Acad Med Singapore 1998; 27:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/43\">",
"      Ramos M, L&oacute;pez de Castro JA. HLA-B27 and the pathogenesis of spondyloarthritis. Tissue Antigens 2002; 60:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/44\">",
"      L&oacute;pez de Castro JA. HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol Lett 2007; 108:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/45\">",
"      L&oacute;pez de Castro JA. HLA-B27: portraying immunodominant viral epitopes. Eur J Immunol 2005; 35:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/46\">",
"      Stewart-Jones GB, di Gleria K, Kollnberger S, et al. Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. Eur J Immunol 2005; 35:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/47\">",
"      Wucherpfennig KW. Presentation of a self-peptide in two distinct conformations by a disease-associated HLA-B27 subtype. J Exp Med 2004; 199:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/48\">",
"      Ben Dror L, Barnea E, Beer I, et al. The HLA-B*2705 peptidome. Arthritis Rheum 2010; 62:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/49\">",
"      L&oacute;pez de Castro JA. The HLA-B27 peptidome: building on the cornerstone. Arthritis Rheum 2010; 62:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/50\">",
"      Atagunduz P, Appel H, Kuon W, et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum 2005; 52:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/51\">",
"      Fiorillo MT, Maragno M, Butler R, et al. CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J Clin Invest 2000; 106:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/52\">",
"      Fiorillo MT, R&uuml;ckert C, H&uuml;lsmeyer M, et al. Allele-dependent similarity between viral and self-peptide presentation by HLA-B27 subtypes. J Biol Chem 2005; 280:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/53\">",
"      Kanaseki T, Blanchard N, Hammer GE, et al. ERAAP synergizes with MHC class I molecules to make the final cut in the antigenic peptide precursors in the endoplasmic reticulum. Immunity 2006; 25:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/54\">",
"      Allen RL, Bowness P, McMichael A. The role of HLA-B27 in spondyloarthritis. Immunogenetics 1999; 50:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/55\">",
"      Allen RL, O'Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol 1999; 162:5045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/56\">",
"      Chan AT, Kollnberger SD, Wedderburn LR, Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 2005; 52:3586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/57\">",
"      Kollnberger S, Bowness P. The role of B27 heavy chain dimer immune receptor interactions in spondyloarthritis. Adv Exp Med Biol 2009; 649:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/58\">",
"      Payeli SK, Kollnberger S, Marroquin Belaunzaran O, et al. Inhibiting HLA-B27 homodimer-driven immune cell inflammation in spondylarthritis. Arthritis Rheum 2012; 64:3139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/59\">",
"      Colbert RA, DeLay ML, Layh-Schmitt G, Sowders DP. HLA-B27 misfolding and spondyloarthropathies. Prion 2009; 3:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/60\">",
"      Mear JP, Schreiber KL, M&uuml;nz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 1999; 163:6665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/61\">",
"      DeLay ML, Turner MJ, Klenk EI, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009; 60:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/62\">",
"      Zeng L, Lindstrom MJ, Smith JA. Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. Arthritis Rheum 2011; 63:3807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/63\">",
"      Haroon N, Tsui FW, Uchanska-Ziegler B, et al. Endoplasmic reticulum aminopeptidase 1 (ERAP1) exhibits functionally significant interaction with HLA-B27 and relates to subtype specificity in ankylosing spondylitis. Ann Rheum Dis 2012; 71:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/64\">",
"      Haroon N, Inman RD. Endoplasmic reticulum aminopeptidases: Biology and pathogenic potential. Nat Rev Rheumatol 2010; 6:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/65\">",
"      Ambarus C, Yeremenko N, Tak PP, Baeten D. Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? Curr Opin Rheumatol 2012; 24:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/66\">",
"      Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990; 63:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/67\">",
"      Taurog JD, Maika SD, Simmons WA, et al. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J Immunol 1993; 150:4168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/68\">",
"      Tran TM, Dorris ML, Satumtira N, et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum 2006; 54:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/69\">",
"      Braem K, Lories RJ. Insights into the pathophysiology of ankylosing spondylitis: contributions from animal models. Joint Bone Spine 2012; 79:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/70\">",
"      Layh-Schmitt G, Colbert RA. The interleukin-23/interleukin-17 axis in spondyloarthritis. Curr Opin Rheumatol 2008; 20:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/71\">",
"      Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011; 13:R95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/72\">",
"      Noordenbos T, Yeremenko N, Gofita I, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012; 64:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/73\">",
"      Gaston JS, Goodall JC, Baeten D. Interleukin-23: a central cytokine in the pathogenesis of spondylarthritis. Arthritis Rheum 2011; 63:3668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/74\">",
"      Tani Y, Tiwana H, Hukuda S, et al. Antibodies to Klebsiella, Proteus, and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. J Rheumatol 1997; 24:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/75\">",
"      Hermann E, Suck&eacute; B, Droste U, Meyer zum B&uuml;schenfelde KH. Klebsiella pneumoniae-reactive T cells in blood and synovial fluid of patients with ankylosing spondylitis. Comparison with HLA-B27+ healthy control subjects in a limiting dilution study and determination of the specificity of synovial fluid T cell clones. Arthritis Rheum 1995; 38:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/76\">",
"      Tinazzi E, Ficarra V, Simeoni S, et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int 2006; 26:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/77\">",
"      Giladi M, Maman E, Paran D, et al. Cat-scratch disease-associated arthropathy. Arthritis Rheum 2005; 52:3611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/78\">",
"      Granfors K, Merilahti-Palo R, Luukkainen R, et al. Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactive arthritis. Arthritis Rheum 1998; 41:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/79\">",
"      Taylor-Robinson D, Gilroy CB, Thomas BJ, Keat AC. Detection of Chlamydia trachomatis DNA in joints of reactive arthritis patients by polymerase chain reaction. Lancet 1992; 340:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/80\">",
"      Wilkinson NZ, Kingsley GH, Jones HW, et al. The detection of DNA from a range of bacterial species in the joints of patients with a variety of arthritides using a nested, broad-range polymerase chain reaction. Rheumatology (Oxford) 1999; 38:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/81\">",
"      Carter JD, Hudson AP. The evolving story of Chlamydia-induced reactive arthritis. Curr Opin Rheumatol 2010; 22:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/82\">",
"      G&eacute;rard HC, Whittum-Hudson JA, Carter JD, Hudson AP. The pathogenic role of Chlamydia in spondyloarthritis. Curr Opin Rheumatol 2010; 22:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/83\">",
"      Gracey E, Inman RD. Chlamydia-induced ReA: immune imbalances and persistent pathogens. Nat Rev Rheumatol 2012; 8:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/84\">",
"      Carter JD, Espinoza LR, Inman RD, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum 2010; 62:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/85\">",
"      Kapasi K, Inman RD. ME1 epitope of HLA-B27 confers class I-mediated modulation of gram-negative bacterial invasion. J Immunol 1994; 153:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/86\">",
"      Laitio P, Virtala M, Salmi M, et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. Eur J Immunol 1997; 27:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/87\">",
"      Penttinen MA, Heiskanen KM, Mohapatra R, et al. Enhanced intracellular replication of Salmonella enteritidis in HLA-B27-expressing human monocytic cells: dependency on glutamic acid at position 45 in the B pocket of HLA-B27. Arthritis Rheum 2004; 50:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/88\">",
"      Ortiz-Alvarez O, Yu DT, Petty RE, Finlay BB. HLA-B27 does not affect invasion of arthritogenic bacteria into human cells. J Rheumatol 1998; 25:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/89\">",
"      Tsui FW, Xi N, Rohekar S, et al. Toll-like receptor 2 variants are associated with acute reactive arthritis. Arthritis Rheum 2008; 58:3436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/90\">",
"      Van Praet L, Van den Bosch F, Mielants H, Elewaut D. Mucosal inflammation in spondylarthritides: past, present, and future. Curr Rheumatol Rep 2011; 13:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/91\">",
"      Danoy P, Pryce K, Hadler J, et al. Association of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's disease. PLoS Genet 2010; 6:e1001195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/92\">",
"      Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006; 20:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/93\">",
"      Van Praet L, Jacques P, Van den Bosch F, Elewaut D. The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol 2012; 8:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/94\">",
"      van der Heijde D, Landew&eacute; R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/95\">",
"      van der Heijde D, Landew&eacute; R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/96\">",
"      van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009; 11:R127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/97\">",
"      Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007; 56:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/98\">",
"      Maksymowych WP, Elewaut D, Schett G. Motion for debate: the development of ankylosis in ankylosing spondylitis is largely dependent on inflammation. Arthritis Rheum 2012; 64:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/99\">",
"      Beyer C, Distler JH. Changing paradigms in spondylarthritis: the myofibroblast signature. Arthritis Rheum 2013; 65:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/100\">",
"      Yeremenko N, Noordenbos T, Cantaert T, et al. Disease-specific and inflammation-independent stromal alterations in spondylarthritis synovitis. Arthritis Rheum 2013; 65:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/101\">",
"      Lories RJ, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 2009; 11:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/102\">",
"      Lories RJ, Luyten FP. Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev 2005; 16:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/103\">",
"      Schett G, Zwerina J, David JP. The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol 2008; 4:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/104\">",
"      Maksymowych WP. Disease modification in ankylosing spondylitis. Nat Rev Rheumatol 2010; 6:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/105\">",
"      Ronneberger M, Schett G. Pathophysiology of spondyloarthritis. Curr Rheumatol Rep 2011; 13:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/106\">",
"      Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010; 233:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/107\">",
"      Uderhardt S, Diarra D, Katzenbeisser J, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010; 69:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/108\">",
"      Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-&gamma;t+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012; 18:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/51/12090/abstract/109\">",
"      Lories RJ, McInnes IB. Primed for inflammation: enthesis-resident T cells. Nat Med 2012; 18:1018.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7792 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-B1BE4F5CD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12090=[""].join("\n");
var outline_f11_51_12090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      KEY OBSERVATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathology of AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic influences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tumor necrosis factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DISEASE ASSOCIATION WITH HLA-B27",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Structure of HLA-B27",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H516012992\">",
"      HLA-B27 subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Subtype and disease association",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Subtype and peptide specific binding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Subtype and peptide conformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CD8+ T cells and molecular mimicry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HLA-B27 heavy chain homodimer formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HLA-B27 protein misfolding and autoinflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25857154\">",
"      Role of ERAP1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25857161\">",
"      Macrophages and AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HLA-B27 transgenic animal models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CYTOKINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Infections and AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Infections in reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11541214\">",
"      - Chlamydia-induced reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Interaction between infection and HLA-B27",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14182679\">",
"      - Infection and innate immunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1221077\">",
"      ROLE OF THE GASTROINTESTINAL TRACT IN SpA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OSTEOIMMUNOLOGY: BONE EROSION AND NEW BONE FORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H427628909\">",
"      ENTHESEAL IL-23 RESPONSIVE T CELLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7792\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7792|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/39/41586\" title=\"figure 1\">",
"      HLA class I diagram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/3/20534\" title=\"figure 2\">",
"      HLA-B27 peptide presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/53/25427\" title=\"figure 3\">",
"      Antigenic peptide processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/43/1718\" title=\"figure 4\">",
"      HLA-B27 homodimer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/57/10135\" title=\"figure 5\">",
"      HLA-B27 induce AS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/12/13505\" title=\"figure 6\">",
"      IL-23 and entheseal T cells in SpA pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7792|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/42/685\" title=\"table 1\">",
"      AS susceptibility genes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13640?source=related_link\">",
"      Diagnosis and differential diagnosis of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6377?source=related_link\">",
"      Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=related_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8696?source=related_link\">",
"      Spondyloarthropathy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_51_12091="Outcome of twin pregnancy";
var content_f11_51_12091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fetal and infant death rates in twin gestations (both fetuses alive at 20 weeks of gestation, n=150,386)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two surviving infants",
"       </td>",
"       <td>",
"        93.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One infant death, one surviving infant",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two infant deaths",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One fetal death, one surviving infant",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two fetal deaths",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One fetal death, one infant death",
"       </td>",
"       <td>",
"        0.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based upon the Matched Multiple Birth File from the US National Center for Health Statistics. Adapted from Johnson, CD, Zhang, J. Obstet Gynecol 2002; 99:698.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12091=[""].join("\n");
var outline_f11_51_12091=null;
var title_f11_51_12092="Causes of neutropenia in HIV";
var content_f11_51_12092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common causes of neutropenia in HIV-infected patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zidovudine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other antiretroviral agents (much less common)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ganciclovir/Valganciclovir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foscarnet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other sulfonamides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyrimethamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acyclovir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentamidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphotericin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-flucytosine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferon alfa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epstein-Barr virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infectious hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dengue fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tularemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brucellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kala-azar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated mycobacterial infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated fungal infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteremia/sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma (small, non-cleaved cell non-Hodgkin's lymphoma most common)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other malignancies with metastatic bone marrow involvement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12092=[""].join("\n");
var outline_f11_51_12092=null;
var title_f11_51_12093="Dry powder inhaler technique in children";
var content_f11_51_12093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F58951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F58951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Techniques for use of various dry powder inhalers in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diskhaler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove mouthpiece cover and pull tray out from device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place disk on wheel with numbers facing up.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rotate disk by sliding tray out and in.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lift back of lid until fully upright so that needle pierces both sides of blister.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep device level while inhaling dose with a rapid and steady flow.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe in rapidly and steadily, as deeply as possible; hold breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove device from mouth and exhale outside device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brush off any powder remaining within device once every week; store device in cool, dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diskus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Open the device and slide the lever until it clicks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep device level while inhaling dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe in rapidly and steadily, as deeply as possible; hold breath.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove device from mouth and exhale outside device; store device in cool, dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Flexhaler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prime the inhaler: This is done only with the initial dose. Holding the inhaler in the upright position, twist the brown grip as far as it will go in one direction, then twist it all the way back in the other direction. A click will be heard during one of the turns. This step should be repeated to complete the priming of the device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Load a dose: Holding the inhaler in an upright position, twist the brown grip as far as it will go in one direction, then twist it all the way back in the other direction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhale the dose: Turn away from the inhaler and breathe out. Then place the mouthpiece in your mouth, close your lips, and inhale deeply.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Twisthaler",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold the inhaler straight up with the pink portion (the base) on the bottom.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove the cap while it is in the upright position to make sure you get the right amount of medicine with each dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hold the pink base and twist the cap in a counter-clockwise direction to remove it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        As you lift off the cap, the dose counter on the base will count down by 1. This action loads the medicine that you are now ready to inhale.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make sure the indented arrow located on the white portion (directly above the pink base) is pointing to the dose counter.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Breathe out normally - do not exhale into the device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place the mouthpiece into your mouth, with the mouthpiece facing towards you, and close your lips tightly around it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhale dose with a rapid and steady flow while holding the Twisthaler horizontal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Remove the mouthpiece from your mouth and hold your breath for 5 to 10 seconds (or as long as you comfortably can).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        When you exhale, be sure that you are not exhaling into the device.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immediately replace the cap and turn in a clockwise direction as you gently press down until you hear a click.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Firmly close the Twisthaler to assure that your next dose is properly loaded.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Be sure that the arrow is in line with the dose-counter window.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store device in cool dry place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The dose counter displays the number of doses remaining. When the unit reads 01, this indicates the last remaining dose. When the counter reads 00, the unit must then be discarded.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12093=[""].join("\n");
var outline_f11_51_12093=null;
var title_f11_51_12094="External PEEP with auto PEEP";
var content_f11_51_12094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    External positive end-expiratory pressure (PEEP) with auto-PEEP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 325px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The use of external positive end-expiratory pressure (PEEP) in the setting of auto-PEEP may be conceptualized by the \"waterfall over a dam\" analogy. In this analogy, the presence of dynamic hyperinflation and 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O of auto-PEEP is represented in the top panel by the reservoir of water trickling over the dam represented by the solid block. In the middle panel, as long as the external PEEP is less than or equal to the amount of auto-PEEP, the amount of water in the upstream reservoir, representing dynamic hyperinflation, does not increase. However, once the amount of water in the reservoir does increase (bottom panel), dynamic hyperinflation worsens. Additional experimental studies done by others suggest that this effect occurs once the external PEEP is greater than approximately 85 percent of the amount of auto-PEEP.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Tobin MJ, Lodato RF, Chest 1989; 96:449.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12094=[""].join("\n");
var outline_f11_51_12094=null;
var title_f11_51_12095="Ulcerated hemangioma perineum";
var content_f11_51_12095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulcerated hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ulceration is the most common complication of hemangiomas. Large segmental lesions, especially in trauma-prone locations, as the one of the perineum depicted above, are at increased risk for ulceration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Denise W Metry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_51_12095=[""].join("\n");
var outline_f11_51_12095=null;
